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Substance use disorders (SUD) impact millions of women aged 15-44 in the 
United States. Unintended pregnancy, which is associated with maternal and infant 
morbidities, is common among women with SUD. Family planning is a leading strategy 
to prevent unintended pregnancy, yet women with SUD report low rates of contraceptive 
use. The goal of this research is to contribute a more nuanced understanding of how 
women with SUD are provided with and use contraception during the childbearing years. 
This dissertation investigates contraceptive provision and initiation trends, 
patterns, and practices among reproductive-age women with and without SUD. Three 
chapters make up this dissertation; each chapter is focused on a different aspect of 
contraceptive care.  
The first chapter describes changes in contraceptive provision between 2000-2017 
for South Carolina Medicaid-enrolled women with and without SUD aged 15-44 at risk 
of unintended pregnancy. Clinical performance measures for contraceptive care endorsed 
by the National Quality Forum were applied to the data to assess annual percentages of 
women provided most or moderately effective contraceptive methods. Contraceptive 
provision of long-acting reversible methods increased more for women with SUD than 
women without SUD over the study period. Provision of most or moderately effective 
methods was substantially lower among women with SUD than their non-SUD 
counterparts.  
The second chapter compares postpartum contraceptive initiation patterns among 
reproductive-age women with and without opioid use disorders (OUD) enrolled in South 
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Carolina Medicaid. This study employed a counterfactual framework to balance the 
distribution of covariates between women with OUD and comparison women without 
OUD. Having an OUD was associated with decreased contraceptive initiation in the 
postpartum period, suggesting that women with OUD face increased barriers to accessing 
postpartum contraceptives than similar women without OUD. 
The third chapter investigates health care providers’ self-reported contraceptive 
counseling practices for their patients with SUD. Interviews were conducted with a 
national sample of women’s health providers. Providers emphasized the importance of 
timing contraceptive discussions appropriately, tailoring information based on patient 
needs and wants, building interpersonal relationships, and prioritizing patients’ 
autonomy. Some providers perceived that long-acting reversible contraceptives were 
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Each year substance use impacts millions of reproductive-age women in the 
United States (US). In 2017, 54.5% of non-pregnant and 11.5% of pregnant women aged 
15-44 years reported alcohol use in the past 30 days (1). In the same year, 14.0% and 
8.5% of non-pregnant and pregnant reproductive-age women, respectively, reported past-
month illicit drug use or prescription drug misuse (1). Substance use can be defined along 
a continuum from abstinence to addiction (2). Not all individuals who use alcohol or 
drugs will develop problems of abuse or dependence. Substance use disorders (SUD) 
diagnoses occur when repeated unhealthy patterns of substance abuse or dependence 
interfere with daily life (3). According to nationally representative data, prevalence 
estimates for lifetime alcohol use disorder and drug use disorder among women aged 18 
and over are 22.7% (4) and 7.7% (5), respectively. These data are not available 
specifically for women aged 15-44 years. 
Unhealthy substance use is associated with a broad range of adverse mental and 
physical health consequences, from acute conditions such as hypertension (6), insomnia 
(7,8) and sudden death (9–11), to chronic illnesses such as heart disease (12,13), 
depression and anxiety (14,15), and chronic liver disease (16), among others. In women 
of reproductive age, substance abuse or dependence can adversely impact reproductive 
health, pregnancy, and child outcomes. Notably, maternal substance use has the potential 
to cause harm to the fetus when substances cross the placenta. Examples of unfavorable 
pregnancy and neonatal outcomes resulting from perinatal substance use include 
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spontaneous abortion, intrauterine growth restriction, preterm birth, low birth weight, 
irritability, hypotonia, poor alertness or abstinence syndrome (17,18). Alcohol, which is a 
widely known teratogen, may also cause birth defects, the most severe of which is fetal 
alcohol syndrome (19). Longer-term effects of prenatal substance exposure on the child 
can include behavioral problems, impaired cognition, or poor socioemotional or language 
development (18,20). 
At the population level, contraception is the most effective primary prevention 
strategy for helping women to avoid unintended pregnancy, reduce abortion, achieve 
healthy birth spacing, and prevent the potentially negative effects of unhealthy substance 
use during pregnancy. Yet, substance-using women have suboptimal family planning 
outcomes. Compared to women without SUD, women with SUD are less likely to use 
contraceptives, especially highly effective methods (21,22), and almost twice as likely to 
have an unplanned pregnancy.  More than 75% of pregnancies among women with SUD 
are unintended (23–25), compared to 45% in the general population (26). From a 
population health perspective, there is an important need to develop targeted policies and 
interventions to reduce unplanned pregnancies and improve contraceptive outcomes for 
this population. 
Trends in contraceptive provision  
Advances in contraceptive technology and increased federal funding for family 
planning programs since the 1960s have transformed the family planning landscape in the 
US. With the increased availability and accessibility of family planning services, most 
individuals in need of safe, effective contraceptive methods can access them. Evidence 
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shows that nearly 100% of women who are sexually active in the US have used 
contraception at some point in time (27).  
While overall contraceptive prevalence in the US has remained stable for several 
decades (28,29), family planning use and delivery patterns have shifted away from less 
effective forms of contraception in favor of highly effective reversible methods in recent 
years. In particular, intrauterine devices (IUD) and implants, or long-acting reversible 
contraceptives (LARC), are growing in popularity. Between 2002-2014, the proportion of 
women aged 15-44 years who used a LARC method increased from 2.4% to 14% 
(29,30). Over the same period, there was a substantial decline in the proportion of women 
who used less effective methods, such as diaphragm, foam, sponge, suppositories, or 
jelly/cream (27–29). On the provision side, it is recommended that providers present 
information about LARC before presenting information on less effective contraceptive 
options (31) because these methods have low failure rates and do not require user 
compliance (32). 
Prior research suggests that increased LARC use or sustained improvements in 
compliance with short-acting reversible contraceptives (SARC) in previous years may 
have played a role in the recently declining unintended pregnancy rate in the US (26,33). 
It follows that remarkably high rates of unintended pregnancy among women with SUD 
may be a result of LARC underutilization or poor compliance with SARC methods in this 
population. A seminal review published in 2015 by Terplan and colleagues reported that 
women with SUD had a 25% lower contraceptive use prevalence than women without 
SUD and that condoms accounted for a median of 62% of contraceptives used, while 
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LARC or sterilization accounted for 8% of use in this population (22). Although many of 
the studies reviewed by Terplan et al were conducted during years in which less effective 
contraceptive methods dominated the family planning landscape, other more recent 
studies have reported similar findings. A 2017 study found that having a SUD diagnosis 
was associated with decreased prescription contraceptive use (21). In this and other 
studies, women with SUD reported LARC use ranging from 5-12% (21,34–36).  
To date, it remains unknown how contraceptive use and delivery patterns for 
women with SUD have changed over time. Identifying gaps in the contraceptive services 
provided to women with SUD is necessary to inform the development of family planning 
programs and to improve the quality of contraceptive care delivery for this population. To 
address this need, the first manuscript of this dissertation describes changes over time in 
contraceptive provision for reproductive-age women with and without SUD utilizing 18 
years of South Carolina (SC) Medicaid data. National Quality Forum (NQF) 
contraceptive care measures were applied to the data to assess population-level rates of 
provision of LARC and most or moderately effective (MME) contraceptive methods. 
Percentages were stratified by SUD and by participant characteristics to assess subgroups 
of women with particularly low provision patterns, indicating a need for increased access 
to contraception for these groups.  
Patterns in postpartum contraceptive initiation 
Increased access to health insurance and health care utilization during pregnancy 
and the postpartum period provide an ideal opportunity for women to access family 
planning, both to reduce potential future unintended pregnancies and to optimize birth 
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spacing. Despite this, there are still many women in the US who do not access 
postpartum contraception and wide variation in postpartum contraceptive use exists 
between states. From 2004-2006, 12% of postpartum women in 12 US states reported not 
using any form of contraception and only 61.7% reported using the most effective forms 
of contraception (37). Between 2003-2009, 24.4% of postpartum women in Oregon 
reported using LARC while only 15.6% women in Michigan reported using these 
methods (38). In a 2008 study conducted among Medicaid-enrolled, postpartum women 
in California, only 41% of the women had a contraception prescription by three months 
after delivery and 40% became pregnant again within 18 months (39). 
Currently, there is limited research assessing postpartum contraceptive initiation 
patterns among women with SUD. In three studies examining postpartum contraceptive 
use in SUD populations, researchers reported varying rates of use of any method (range 
25.5-50%) but fairly consistent rates of use of LARC or female sterilization (7.4-11.5%) 
(25,40,41). In the only study to examine contraceptive use outcomes among women with 
SUD past 90 days postpartum, 66.7% and 65.3% of study participants reported using any 
contraceptives at 12 and 24 months postpartum, respectively (25). Because these studies 
restricted their sample to women with opioid use disorder (OUD) or other SUD, it is still 
unclear how postpartum contraceptive initiation differs among women with SUD 
compared to women without SUD. Moreover, more research is needed to understand the 
influence of SUD type on postpartum contraceptive outcomes, specifically how 
postpartum contraceptive use compares for women with OUD and those with other 
alcohol and drug disorders. 
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To address these gaps, the second manuscript in this dissertation examines 
patterns in postpartum initiation of MME contraceptive methods at multiple time points, 
including within the immediate postpartum period and by 3, 6, and 12 months 
postpartum, among women with and without OUD. Because women with OUD may be 
systematically different than women without OUD, including those with non-opioid 
substance use disorders (non-opioid SUD) and women without SUD, this study used 
propensity score methods to adjust for baseline differences between the study groups. 
The associations between OUD and postpartum contraceptive initiation were examined 
using multivariable and weighted logistic regression and the predicted probabilities of 
study outcomes were calculated and graphed.  
Practices related to contraceptive counseling 
Contraceptive counseling – the process by which patients and health care 
providers consider the patients’ reproductive life goals, discuss information related to the 
safety, efficacy, and side effects of a complete range of contraceptive methods, and 
jointly choose a contraceptive method to help patients successfully reach their goals (42)  
– is a key aspect of family planning services provision. While a variety of personal, 
interpersonal and structural factors impact patients’ uptake and continued use of 
contraception, contraceptive counseling may positively influence patients’ decision-
making about method choice and initiation of chosen methods (43–45).  
Data about how contraceptive counseling is performed in the US primarily come 
from objective observations of contraceptive counseling interactions or from patients’ or 
providers’ self-report about their counseling experiences. Few studies to date have 
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collected data on contraceptive counseling through direct observation; the largest US 
study to do so was the Patient-Provider Communication about Contraception (PPCC) 
study. This cohort study, which recruited women aged 16-53 years seeking contraceptive 
care in San Francisco area clinics between 2009 and 2012, audio-recorded a total of 342 
clinical encounters (46). Multiple analyses using PPCC data show that there is wide 
variation in contraceptive counseling practices, especially related to information 
exchange and communication strategies, across providers in different settings as well as 
within the same setting (47–51). For instance, in one analysis providers discussed side 
effects of any methods at 97% of the visits (47). However, another analysis revealed that 
providers told patients about hormonal side effects in only 38% of the visits in which 
women selected a hormonal IUD (46). 
The inconsistencies in family planning counseling and provision observed in the 
PPCC study may be partly attributed to health care providers efforts to implement 
patient-centered care, which involves personalizing care for each patient (52). Another 
analysis with PPCC data reported that counseling was largely patient-driven, with 
providers and patients engaging in a dynamic exchange of information to mutually decide 
on the best contraceptive method for patients (53). This form of iterative patient-provider 
communication, by which providers share their medical knowledge and patients share 
their unique needs and preferences, is known as shared-decision making (SDM) (54). In 
the context of family planning provision, SDM may be more effective to promote 
contraceptive use than provider-driven decision-making models, which can inhibit trust-
building (55). SDM during contraceptive provision is associated with increased overall 
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patient satisfaction and satisfaction with a chosen method (56). Moreover, research shows 
that SDM is consistent with women’s preferences for counseling interactions (57). 
The PPCC study was conducted among women who desired contraceptive 
services, so no insight can be gained from this study about when contraceptive counseling 
typically happens. Prior research shows that women receive contraceptive counseling 
during pregnancy and the postpartum period more often than in other time periods. 
According to national survey data, approximately 80% of women have received prenatal 
contraceptive counseling (58–64), and nearly 86% and 72% of women have received 
postpartum counseling or counseling in both time periods, respectively (61). In contrast, 
only 3%, 7%, and 29% of non-pregnant, non-postpartum women report sterilization 
counseling (65,66), emergency contraception counseling (67), or any birth control 
counseling (68), respectively.  
There is a clear gap in the literature regarding how contraceptive counseling is 
performed for women with SUD. To fill this gap, the third manuscript in this dissertation 
applies qualitative methods to examine health care providers’ self-reported contraceptive 
counseling practices for women with SUD. The study examines several aspects of 
contraceptive counseling provision, including the context in which counseling takes 
place, information shared at visits, and communication approaches, and explored 
variation in reported practices based on patients’ stage of addiction recovery.  This study 




The overarching goal of this dissertation is to examine contraceptive provision 
and initiation trends, patterns, and practices among reproductive-age women with and 
without SUD. This research was driven by an interest in considering upstream 
approaches to reduce the potentially negative effects of prenatal substance exposure on 
maternal and child health. The empirical studies that makeup this dissertation focus on 
providing insights into the role of substance abuse and dependence on contraceptive 
provision and use outcomes and may help inform public policy and clinical practices to 
improve access to and quality of contraceptive care for women and adolescents affected 
by substance abuse. The specific aims of the dissertation are: 
Aim 1: To describe changes from 2000-2017 in contraceptive provision for South 
Carolina Medicaid-enrolled women with and without SUD aged 15-44 at risk of 
unintended pregnancy. 
Aim 2: To compare postpartum contraceptive initiation patterns in South Carolina 
Medicaid-enrolled women with and without OUD aged 15-44. 
Aim 3: To investigate health care providers’ contraceptive counseling practices for 
reproductive-age women with SUD in varying stages of addiction recovery. 
Dissertation organization 
This dissertation is organized into five chapters. Following this introduction, there 
are three distinct studies with accompanying tables and figures at the end of the chapters 
and supplementary material included in the appendices. Chapter 2 describes changes in 
contraceptive provision from 2000-2017 for reproductive-age women with and without 
SUD enrolled in SC Medicaid. Chapter 3 reports the postpartum contraceptive behaviors 
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of women with OUD compared to women with non-opioid SUD and women without 
SUD. Chapter 4 presents health care providers’ self-reported contraceptive counseling 
practices for their patients with SUD. Chapter 5 summarizes each chapter, considers the 
dissertation strengths and limitations, and reflects on implications for clinical and public 
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ABSTRACT 
Objective: To describe changes in contraceptive provision between 2000-2017 for South 
Carolina Medicaid-enrolled women with and without substance use disorders (SUD) aged 
15-44 at risk of unintended pregnancy.  
Methods: South Carolina Medicaid administrative billing data were used. We report 
2000-2017 annual percentages of women provided with a: 1) most or moderately 
effective (MME) contraceptive method and 2) long-acting reversible contraceptive 
(LARC) method. Percentages over time were stratified on the basis of SUD type, age, 
race-ethnicity, rural-urban county of residence, postpartum status, health plan type, and 
benefit type. 
Results: Between 2000-2017, MME provision for women with and without SUD 
increased from 8.1% to 24.5% and 9.0% to 29.9%, respectively. LARC provision for 
women with and without SUD increased from 0.27% to 5.27% and 0.37% 4.18%, 
respectively. Compared to women without SUD, women with SUD had lower rates of 
MME uptake among women aged 21-44 and higher rates of MME uptake among women 
aged 15-20. Absolute rates of LARC provision were greater among women with SUD 
aged 15-20 than women with or without SUD in all other age groups.  
Conclusions: The percentages of South Carolina Medicaid-enrolled women with and 
without SUD provided MME and LARC methods substantially increased between 2000-
2017. Adolescent women with SUD had higher rates of contraceptive provision than 
adolescent women without SUD over the study period. An opportunity for improvement 
in contraceptive provision exists for South Carolina Medicaid-enrolled women of 
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Addressing the family planning needs of women with substance use disorders 
(SUD) is an important public health priority since women with SUD report high rates of 
unintended pregnancy. More than 75% of pregnancies among women with SUD are 
unintended,1–4 compared with 45% in the general United States (US) population.5 
Unintended pregnancies are associated with increased risk for maternal and infant 
morbidities and adverse perinatal outcomes, such as low birth, postpartum depression, 
and shortened duration of breastfeeding,6 and are associated with high economic costs for 
society and health systems.7  
Given that most unintended pregnancies occur because of contraceptive non-use 
or incorrect use, several studies have sought to assess contraceptive use outcomes in 
women with SUD. The existing literature states that women with SUD have lower rates 
of contraceptive use and select less effective methods than their non-SUD counterparts. A 
2015 review of 24 studies reported that, on average, 55% of substance-using women used 
any form of contraception, compared with 81% of women who did not engage in 
substance use.8 In that study, condoms were the most commonly chosen method among 
women with SUD.8 A more recent study found that SUD was associated with decreased 
odds of prescription contraceptive use and of choosing the most effective reversible 
methods.9 What is not known, and where research is lacking, is whether contraceptive 
uptake is uniformly low among women with SUD, or only low in certain subgroups in 
this SUD population. Furthermore, it is unknown how contraceptive provision has 
changed over time for this population.  
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  Limited US data are available for investigations related to contraceptive provision 
in substance-using populations. Administrative claims data, which capture reimbursement 
to health care providers for medical and pharmacy services received by insurance 
beneficiaries, allow for such studies to be conducted. Contraceptive care measures 
(CCM) can be used with claims data and have been successfully used in previous studies 
to gauge trends in prescription contraceptive provision and uptake.10,11 CCM, or clinical 
performance measures for contraceptive care, which were developed by the U.S. Office 
of Population Affairs and Centers for Disease Control and Prevention (CDC) and 
endorsed by the National Quality Forum in November 2016, are the first validated 
indicators in reproductive health to measure access to and quality of contraceptive care.12 
As of yet, CCM have not been adapted for use within a subpopulation, such as women 
with SUD.  
This study applied the NQF-endorsed CCM to South Carolina (SC) Medicaid 
claims data to examine changes in contraceptive provision from 2000-2017 for women 
aged 15-44 at risk of unintended pregnancy. In accordance with the CCM, we examined: 
1) the percentage of women aged 15-44 years provided with a most effective 
(sterilization, intrauterine devices or systems (IUD/IUD), implants) or moderately 
effective (injectables, oral pills, patch, ring, or diaphragm) (MME) contraceptive method; 
and, 2) the percentage of women who received only a long-acting reversible 
contraceptive (IUD/IUS, implant) (LARC) method.13 Analyses were stratified on the 
basis of whether or not study participants received a clinical diagnosis for SUD in the 
measurement year. Given documented barriers in access to family planning services and 
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contraceptive use by women with SUD, it is important to identify patterns of 
contraceptive provision for this population, while also identifying subgroups of women 
with particularly low contraceptive uptake whom may benefit from targeted intervention 
or policy initiatives.  
METHODS 
Data  
We examined data of SC Medicaid beneficiaries aged 15-44 years who were 
enrolled in a Medicaid managed care (MMC) or fee-for-service (FFS) health plans 
anytime between 2000-2017. The study years were selected to parallel the dramatic 
increase in opioid use in the US. Through a data use agreement, de-identified data were 
obtained from the SC Office of Research and Statistics and SC Budget and Control 
Board. The data include complete medical and pharmacy claims for Medicaid 
beneficiaries during the study period in addition to patient eligibility files, which contain 
enrollment start and end dates and demographic information. The Clemson University 
institutional review board approved this study. 
Substance use disorders  
We identified women with SUD on the basis of International Classification of 
Diseases, 9th and 10th Revision (ICD-9 and ICD-10) diagnosis and procedure codes, 
Healthcare Common Procedure Coding System (HCPCS) codes, and National Drug Code 
(NDC) numbers. We defined SUD as: 1) having a primary or secondary diagnosis of 
alcohol or drug abuse or dependence in >1 inpatient or emergency department claims or 
>2 outpatient claims on different dates in the measurement year; or, 2) receiving 
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medication for opioid or alcohol dependence in the measurement year (Appendix A). 
Tobacco use was excluded from our definition of SUD as it is not reliably captured in 
claims data.14  
Contraceptive provision measures 
Outcomes were defined as the percentage of women aged 15-44 years at risk of 
unintended pregnancy who were provided with a MME method or a LARC method.  As 
defined in the CCM specifications, women were at risk of unintended pregnancy if they 
were not pregnant, not infecund, or had a pregnancy that ended in ectopic pregnancy, 
stillbirth, miscarriage, or induced abortion in the measurement year.15 Women who gave 
birth in the final two months of the measurement year were excluded because postpartum 
follow up, which is a common time for contraceptive initiation, was not available for 
these women due to the timing of birth. Women who had a LARC method removed in the 
measurement year and did not receive a subsequent LARC or MME method in that year 
were excluded from the numerator. Steps and ICD-9, ICD-10, HCPCS, and NDC codes 
used to calculate the CCM are listed in Appendix B.  
Stratifying Variables 
Stratifying variables included age (15-17, 18-20, 21-24, 25-29, 30-34, 35-39, 40-
44), race-ethnicity (non-Hispanic white, non-Hispanic black, Hispanic, other races-
ethnicities), postpartum status during the measurement year (yes or no), county of 
residence (urban or rural), health plan type (FFS or MMC) and benefit type (full 
Medicaid or family planning limited benefit (FPLB)). We used the US Department of 
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Agriculture’s Urban Influence Codes to identify whether beneficiaries resided in an urban 
(metropolitan) or rural (nonmetropolitan) county (Appendix C).16  
Statistical analysis 
Women enrolled in Medicaid through the FPLB program were included in the 
analysis regardless of their continuous enrollment status; for beneficiaries with full 
Medicaid benefits, we excluded women with more than a 45 day gap in coverage during 
the measurement year.15 We generated descriptive statistics for the sample by year. We 
calculated annual unadjusted rates of MME and LARC provision for each measurement 
year from 2000-2017 stratified by whether or not participants had a diagnosed SUD. We 
decomposed SUD into 5 mutually exclusive types: alcohol use disorder (AUD), cannabis 
use disorder (CANUD), opioid use disorder (OUD), other drug use disorder (DUD) (e.g. 
cocaine, methamphetamine, hallucinogens), and polysubstance use disorder (PSUD). 
Additional analyses estimated annual percentages in contraceptive provision stratified by 
age, race-ethnicity, urban-rural county of residence, postpartum status, health plan type, 
and benefit type. 
RESULTS 
Table S2.1 shows the inclusion/exclusion process for calculating the denominator 
of the CCM for unadjusted analyses. After excluding women who were infecund due to 
non-contraceptive reasons, who were pregnant and did not deliver in the measurement 
year, or who had a pregnancy ending in November-December of the measurement year, 
the final sample size of women included in the denominator ranged from 137,342 to 
235,949 across study years. 
 25 
  Table S2.2 reports the characteristics of the sample for each year of the study 
period. Although most study participants did not have a diagnosed SUD (>97.5% across 
years), the percentage of women with a SUD more than doubled over the study period, 
from 1.09% in 2000 to 2.23% in 2017. The percentage of participants with an OUD 
increased from 2.07% in 2000 to 22.6% in 2017. The proportion of women with an AUD 
or other DUD decreased from 25.4% and 18.1% in 2000 to 9.14% and 6.50% in 2017, 
respectively. On average across study years, a majority of women in the sample were 
older, non-Hispanic black, never married, not pregnant in the measurement year, or 
resided in urban counties. Most participants were enrolled in full Medicaid or in a FFS 
plan. The number of participants enrolled in MMC increased from 0.69% in 2000 to 
34.3% in 2017 while the number of women enrolled in a FPLB program decreased from 
36.1% in 2000 to 18.2% in 2017. 
MME Provision  
Figure 2.1 shows the proportion of participants with and without SUD provided a 
MME method from 2000-2017. MME provision for women with SUD increased from an 
estimated 8.10% to 24.5% over this period. MME provision for women without SUD 
increased from an estimated 9.00% to 29.9% in the same period. For women with SUD, 
MME provision increased more than three-fold between 2000-2006, decreased 
approximately 23.0% from 2006-2011, increased more than 47.0% between 2011-2013, 
and decreased 15.5% from 2013-2017.  The percentage of women provided a MME 
method increased across all SUD types (Figure S2.1). Women with CANUD had the 
greatest increase in MME provision during the study years (10.9% in 2000 to 34.5% in 
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2017), while the smallest increase in MME provision was observed for women with OUD 
(6.50% in 2000 to 16.4% in 2017). 
MME provision increased more from 2000-2017 for women with SUD than 
women without SUD among participants aged 15-20 (SUD: 5.70% to 41.2%; No SUD: 
6.00% to 33.8%) and increased less during this period for women with SUD relative to 
women without SUD among participants aged 21-44 (SUD: 8.80% to 21.8%; No SUD: 
10.8% to 28.2%) (Figure 2.2). A deeper analysis of MME provision by age revealed that 
adolescent women with SUD aged 15-17 had a greater increase in MME provision over 
the study period compared to adolescent women aged 18-20 (Figure S2.2). Contraceptive 
provision increased less for older adult women compared to younger adult women over 
the study period for both women with and without SUD (Figures S2.3 and S2.4).  
In race-stratified MME provision trends, the greatest increase in MME provision 
was observed among non-Hispanic black women with SUD (7.80% in 2000 to 31.0% in 
2017) followed by non-Hispanic black women without SUD (7.90% in 2000 to 30.4% in 
2017) (Figure S2.5).  Among non-Hispanic white participants and participants of other 
racial-ethnic backgrounds, smaller increases in rates of MME provision were observed in 
women with SUD than women without SUD. Across rural-urban county of residence, the 
percentage of women provided a MME method increased less for women with SUD than 
for women without SUD between 2000-2017 (SUD, rural: 7.80% to 25.8%; No SUD, 
rural: 10.0% to 31.6%; SUD, urban: 8.20% to 24.3%; No SUD, urban: 9.50% to 27.7%) 
(Figure S2.6). 
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The percentage of postpartum women provided a MME method more than 
doubled among women with SUD (23.6% to 52.9%) and women without SUD (25.0% to 
59.4%) from 2000-2017 (Figure S2.7). Smaller increases in MME provision during this 
period were observed among non-postpartum women with SUD (3.90% in 2000 to 18.5% 
in 2017) relative to women without SUD (6.50% in 2000 to 27.6% in 2017). Among 
women enrolled in MMC and FFS health plans, MME provision increased less from 
2000-2017 for women with SUD compared to women without SUD (SUD, MMC: 6.20% 
to 24.6%; No SUD, MMC: 5.00% to 30.7%; SUD, FFS: 8.20% to 24.1%; No SUD, FFS: 
9.20% to 40.9%) (Figure S2.8). Overall, MME provision was generally higher for FPLB 
program beneficiaries than among women enrolled in full Medicaid (Figure S2.9). 
Among women enrolled in the FPLB program, the proportion of women with a diagnosed 
SUD provided a MME method increased from 13.2% in 2000 to 27.1% in 2017, while 
the proportion of women without SUD provided a MME method increased from 8.30% in 
2000 to 33.4% to 2017. 
LARC Provision  
Figure 2.3 displays SUD-stratified LARC provision percentages for each year of 
the study period from 2000-2017. The proportion of women with SUD provided a LARC 
method increased from 0.27% in 2000 to 5.27% in 2017. The percentage of women 
without a SUD provided a LARC method increased from 0.37% in 2000 to 4.18% in 
2017. Between 2008-2017, LARC provision increased nearly 82.0% for women with 
SUD and 27.0% for women without SUD. Though LARC provision increased across all 
types of SUD from 2000-2017, participants with CANUD had the greatest increase 
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(0.37% in 2000 to 8.07% in 2017), while women with OUD and other DUD had the 
lowest increases over this period (OUD: 0.00% to 2.50%; other DUD: 0.37% to 2.69%) 
(Figure S2.10). 
Among women with SUD aged 15-20, LARC provision increased from 0.00% in 
2000 to 8.49% in 2017, which was more than double the increase of LARC provision for 
women without SUD aged 15-20 (0.18% in 2000 to 3.96% in 2017) (Figure 2.4). LARC 
provision increased only slightly more for women with SUD than women without SUD 
aged 21-44 years between 2000 and 2017 (SUD: 0.34% to 4.76%; No SUD: 0.48% to 
4.28%). Among women with and without SUD aged 15-20, LARC provision increased 
more over the study period for women with SUD aged 18-20 than for women without 
SUD aged 18-20 and women in both groups aged 15-17 (Figure S2.11). Among adult 
women, LARC provision rates were higher for younger women than older women among 
women with and without SUD (Figures S2.12 and S2.13). Among adult women aged 21-
44, women with SUD aged 21-29 years had the greatest increase in LARC provision over 
the study period.  
Among all races-ethnicities, the percentage of women provided a LARC method 
increased more for women with SUD than women without SUD over the study period 
(Figure S2.14). The greatest increase occurred among non-Hispanic black women with 
SUD (0.14% in 2000 to 6.88% in 2017), followed by non-Hispanic white women with 
SUD (0.47% in 2000 to 4.83% in 2017), and then women of other races-ethnicities with 
SUD (0.00% in 2000 to 4.10% in 2017). Among women residing in rural and urban 
counties, LARC provision also increased more between 2000-2017 for women with SUD 
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than for women without SUD (SUD, rural: 0.30% to 4.35%; No SUD, rural: 0.35% to 
3.65%; SUD, urban: 0.26% to 5.51%; No SUD, urban: 0.41% to 4.25%) (Figure S2.15). 
From 2000-2017, overall LARC provision rates were significantly greater for 
postpartum women than non-postpartum women (Figure S2.16). Among non-postpartum 
women, LARC provision increased similarly for women with and without SUD (SUD: 
0.00% in 2000 to 2.28% in 2017; No SUD: 0.48% in 2000 to 4.28% in 2017), while rates 
of LARC provision increased more for postpartum women with SUD relative to 
postpartum women without SUD between 2000-2017 (SUD: 1.24% to 19.5%; No SUD: 
1.29% to 16.7%). Across health plan types, smaller increases in rates of LARC provision 
were observed for participants enrolled in MMC than FFS plans (Figure S2.17). LARC 
provision increased from 0.27% in 2000 to 7.06% in 2017 for women with SUD and 
from 0.38% in 2000 to 5.19% in 2017 for women without SUD who were enrolled in FFS 
Medicaid. Among FPLB and full Medicaid beneficiaries, LARC provision increased 
more for women with SUD than women without SUD between 2000-2017 (SUD, FPLB: 
0.00% to 5.69%; No SUD, FPLB: 0.30% to 4.45%; SUD, full Medicaid: 0.30% to 5.25%; 
No SUD, full Medicaid: 0.43% to 4.05%) (Figure S2.18).  
DISCUSSION 
We examined SUD-stratified percentages in contraceptive provision from 2000-
2017 among SC Medicaid-enrolled women aged 15-44 at risk of unintended pregnancy. 
We found that MME provision for women with and without a diagnosed SUD more than 
tripled during the 2000-2017 study period and that annual rates of MME provision in this 
study were similar to those reported in other studies using the CCM.10,17 While overall 
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trends for women with and without SUD were generally parallel, our data show that 
women with SUD had lower absolute rates of MME contraceptive provision and uptake 
than women without SUD, which is consistent with previous reports.8,9,18 
The pattern of MME provision reported here did not follow trends reported in a 
recent study conducted among a national sample of commercially-insured women aged 
15-44. In that study, MME provision increased steadily between 2005-2013, followed by 
a slight decrease in 2013.10 In contrast, MME provision in our sample increased sharply 
through 2005, decreased from 2005-2012, increased again in 2013, and finally decreased 
from 2013-2017. SC did not expand Medicaid under the Affordable Care Act, so the 
pattern of MME provision in later years likely reflects that fact. SC Medicaid began 
providing reimbursement for postpartum LARC in 2012, which would account for the 
steep increase in MME provision observed in 2013. However, we have no theories to 
explain why the percentage of women provided a MME method increased sharply from 
2002-2005 and then decreased thereafter through 2012. 
We observed that the pattern of MME provision largely did not change 
differentially by SUD type over the study period. Notably, women with OUD had the 
greatest decline in MME provision during later study years and the lowest absolute 
percentage of MME uptake in 2017. While we observed increasing rates of CANUD, 
OUD, and PSUD and decreasing rates of AUD and other DUD in this study, OUD rates 
increased most rapidly during the study period, consistent with the national opioid 
epidemic. Many innovative strategies have been developed and implemented to increase 
access to family planning services for women with OUD. While family planning 
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interventions and initiatives targeting women with OUD may be a more cost-effective use 
of resources than interventions aimed at other SUD populations, it is important that all 
women receive equitable access to family planning and reproductive health services. 
Also of note in this study is the wide gap in MME provision observed between 
women with SUD aged 15-20 years and those aged 21-44 years. Since 2003, annual 
MME provision rates for women with SUD aged 15-20 were approximately double those 
of women with SUD aged 21-44.  In later study years, women with SUD aged 15-20 had 
higher absolute rates of MME uptake than women without SUD in both age groups.  
Among adolescent women, MME and LARC provision was higher among women with 
SUD than women without SUD. These findings are important because they show that 
MME provision for women with SUD is not lower than women without SUD during the 
early reproductive years. Adolescent beneficiaries of SC Medicaid remain enrolled in the 
state’s program through age 19. Accordingly, adolescents with SUD may have more 
consistent access to health care as well as counseling about contraceptive methods than 
adult women with SUD. As substance-using women enter adulthood, they may face extra 
barriers to accessing health insurance, health care, and family planning services, which 
could explain decreased rates of contraceptive provision for women with SUD aged 21-
44 in this study. More longitudinal investigations of contraceptive adherence and 
discontinuation patterns among women with SUD are needed to identify modifiable 
factors that can be targeted to facilitate contraceptive continuation for women who 
discontinue using contraceptives after aging out of SC Medicaid. 
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This study’s second main finding was that the percentage of women provided a 
LARC method increased significantly during the study period. For all women, LARC 
provision rates more than tripled between 2000-2006 and more than doubled between 
2006-2008. These findings are similar to national trends in LARC use and provision, 
which have increased steadily over the past two decades 19,20. However, LARC provision 
rates for women without SUD in our study were lower than national estimates for 
comparable study years, suggesting that LARC uptake has not increased as rapidly for SC 
Medicaid beneficiaries as it has for US women of a similar age. For example, the 2014 
prevalence of LARC use in the US population was 14.3% 20 compared to 4.17% for 
women without SUD in our data. We observed a greater increase in LARC provision 
over the study period for women with SUD relative to those without SUD. Women with 
SUD also had the highest absolute rates of LARC uptake since 2013. This finding is 
notable primarily because it contradicts research reporting that SUD is associated with 
decreased LARC selection.9 Overall, rates of LARC uptake among women with SUD in 
our study were similar to the range of 5%-12% reported across studies.2,3,8,9,21   
According to the OPA, benchmarks should not be set for LARC provision 
measures to discourage coercive contraceptive practices. Rather, the LARC measure 
should be used to identify subgroups of women with provision below 1%-2%, indicating 
that excessive barriers to LARC access exist for those groups.13 LARC provision below 
2% was not detected in any stratum in this study, suggesting that there are no unnecessary 
barriers that prevent SC Medicaid-enrolled, reproductive-age women from obtaining 
LARC methods. SC has a longstanding and robust Medicaid family planning expansion 
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program that covers reproductive health and preventive services for low-income women 
who do not qualify for full Medicaid. SC was also the first state in the US to allow 
reimbursement for immediate postpartum LARC placement. Longstanding policies to 
improve LARC access and availability in the state are likely responsible for generally 
high LARC rates observed across all subgroups of this study in recent years.  
For groups with low LARC access, research has shown that reducing financial 
barriers to LARC can increase utilization. The Contraceptive CHOICE study found that 
when study participants were offered their choice of any contraceptive method for free, 
two-thirds of women chose LARC.22 Reimbursement policies to remove barriers to 
immediate postplacental LARC insertion after childbirth have also been shown to 
increase LARC uptake among women enrolled in Medicaid.11 In addition to appropriate 
policies to remove financial barriers to use, potential strategies to improve access include 
counseling and education about all contraceptive methods to help women make informed 
choices about methods that best suit their needs and preferences, provider training to 
perform insertions and removals, and primary care incentives to provide LARC to 
women. 
 Limitations 
Our study findings should be interpreted with certain limitations in mind. A 
primary limitation of the CCM is correctly calculating the denominator of women at risk 
of unintended pregnancy. Claims data do not contain information on sexual activity, 
pregnancy seeking or pregnancy intentions, which are important considerations when 
determining risk of unintended pregnancy. Moreover, because the CCM do not include a 
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lookback period, the measures do not capture contraceptive use or medical procedures, 
such as hysterectomy, prior to the measurement year. Based on these limitations, it is 
possible that we overestimated the denominator by including women who already had a 
LARC placed or underwent a contraceptive or non-contraceptive sterilization procedure 
before the measurement year. If this were true, we may have underestimated the annual 
percentages of women provided a MME or LARC method. Because our measurement of 
contraceptive provision and uptake was based on claims data and not actual prescriptions, 
it is also possible that we missed capturing some women who should have been included 
in the numerator. Further, claims data may underestimate the percentage of people with a 
SUD because SUD diagnoses do not appear in the data unless they are related to the 
service being billed. All studies based on administrative billing records rely on the 
accuracy and completeness of providers’ clinical documentation and are subject to bias. 
In addition, because this research was conducted among SC Medicaid-enrolled women 
aged 15-44 at risk of unintended pregnancy, findings reported here may not be 
generalizable to other populations or settings. Finally, because the CCM are outcomes-
based measures that do not take into consideration the process of contraceptive care 
delivery, we cannot draw any conclusions about the quality of contraceptive services 
provided to study participants or the factors responsible for the observed trends.  
CONCLUSION 
This study found that contraceptive provision and uptake increased more than 
200% between 2000-2017 for reproductive-age women enrolled in SC Medicaid. MME 
provision increased 232.2% for women without SUD and 202.5% for women with SUD 
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during the study period. From 2012-2017, LARC provision for women with SUD 
increased by 88.2%, with women with SUD having higher absolute rates of LARC 
uptake after 2012 than women without SUD. Women with SUD aged 15-20 had greater 
increases in MME and LARC provision over the study period than women without SUD 
aged 15-20 and women with and without SUD aged 21-44.  Adolescent women with 
SUD also had the highest absolute rates of contraceptive uptake after 2008. Contrary to 
previous research, these data suggest that women with SUD may not have lower rates of 
contraceptive use than women without SUD during their adolescence and young 
adulthood, but only once they transition into the later reproductive years. Further research 
is needed to identify factors behind the trends and patterns observed here. Future 
investigations should also examine contraceptive discontinuation patterns in adolescents 
and young adult women with SUD, while identifying factors related to continuation 
through later adulthood. A better understanding of facilitators to contraceptive use and 
adherence through the later reproductive years for women with SUD may help substance-
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Figure 2.1. The percentage of South Carolina Medicaid-enrolled women with and without a substance use disorder aged 15-44 
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Figure 2.2. The percentage of South Carolina Medicaid-enrolled women with and without a substance use disorder provided a 



























Reported by age, % 
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Figure 2.3. The percentage of South Carolina Medicaid-enrolled women with and without a substance use disorder aged 15-44 
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Figure 2.4. The percentage of South Carolina Medicaid-enrolled women with and without a substance use disorder provided a 


























Reported by age, % 
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Table S2.1. Inclusion and exclusion criteria used to calculate the denominator of the contraceptive care measures for the main 
analyses 
 2000 2001 2002 2003 2004 2005 2006 2007 2008 
Inclusion criteria for the study          
Total enrollees aged 15-44 years 
meeting enrollment criteria* 139,978 155,657 176,859 176,473 173,923 177,183 168,072 148,200 147,597 
Exclusion criteria for 
contraceptive care measures          
Infecund for non-contraceptive 
reasons  365 466 716 669 570 558 539 553 540 
Still pregnant at the end of the 
measurement year 5 6 5 3 6 8 11 7 9 
Pregnancy ending in November-
December of the measurement 
year  2,266 2,391 2,515 2,898 2,613 2,755 2,816 2,336 2,038 
Final number of women included 
in the denominator 137,342 152,794 173,623 172,903 170,734 173,862 164,706 145,304 145,010 
 
*Enrollment criteria differ based on benefit type. Women with full Medicaid benefits were included in the study if they were continuously enrolled in 
the measurement year (i.e. no more than a 45 day gap in enrollment). Women enrolled in the family planning limited benefit program were included 







Table S2.1 (continued). Inclusion and exclusion criteria used to calculate the denominator of the contraceptive care measures 
for the main analyses 
 2009 2010 2011 2012 2013 2014 2015 2016 2017 
Inclusion criteria for the study          
Total enrollees aged 15-44 years 
meeting enrollment criteria* 146,707 154,853 171,736 184,216 190,421 219,578 233,843 240,786 234,902 
Exclusion criteria for 
contraceptive care measures          
Infecund for non-contraceptive 
reasons  690 726 723 634 573 748 754 848 852 
Still pregnant at the end of the 
measurement year 8 6 8 5 5 11 170 708 486 
Pregnancy ending in November-
December of the measurement 
year  1,941 2,020 2,090 2,268 2,239 2,606 3,176 3,281 3,267 
Final number of women included 
in the denominator 144,068 152,101 168,915 181,309 187,504 216,213 229,743 235,949 230,297 
 
*Enrollment criteria differ based on benefit type. Women with full Medicaid benefits were included in the study if they were continuously enrolled in 
the measurement year (i.e. no more than a 45 day gap in enrollment). Women enrolled in the family planning limited benefit program were included 


























use disorder, % 98.9 98.9 98.8 98.8 98.8 98.8 98.6 98.4 98.4 
Substance use 
disorder*, % 1.09 1.07 1.18 1.19 1.20 1.25 1.41 1.59 1.62 
Alcohol use 
disorder 25.4 28.4 25.0 23.5 21.1 18.0 16.8 16.1 16.5 
Cannabis use 
disorder  17.8 19.3 20.2 20.2 22.5 22.7 15.5 20.9 20.7 
Opioid use 
disorder 2.07 2.68 2.87 3.36 3.61 3.50 4.77 4.68 6.26 
Other drug use 
disorder  18.1 18.3 20.1 19.7 19.5 23.3 22.9 20.2 18.7 
Polysubstance 
use disorder 36.7 31.3 31.8 33.2 33.3 32.5 36.0 38.1 37.8 
Age, %          
15-20 37.0 36.5 36.0 35.8 35.8 35.5 34.9 35.1 35.8 
21-44 63.0 63.5 64.0 64.2 64.2 64.5 65.1 64.9 64.2 
Race-ethnicity, 
%          
Non-Hispanic 
white 39.7 39.8 40.0 40.7 41.1 41.6 41.7 41.3 41.6 
Non-Hispanic 
black 56.3 56.1 55.8 55.1 54.5 53.9 53.6 53.5 53.0 
Other race-
ethnicity 4.05 4.06 4.17 4.17 4.35 4.56 4.71 5.03 5.35 
Rural/urban 
residence, %          
Rural 32.0 31.8 31.5 32.0 31.6 31.0 31.0 31.2 30.6 
Urban 68.0 68.2 68.5 68.0 68.4 69.0 69.0 68.8 69.4 
Postpartum, %          
Yes 13.6 12.3 10.9 10.6 11.4 11.8 13.4 14.0 13.7 
No 86.4 87.7 89.1 89.4 88.6 88.2 86.6 86.0 86.3 
Health plan 





managed care 0.69 1.41 2.39 3.30 3.04 2.76 5.01 6.07 8.71 
Fee-for-service 99.3 98.6 97.6 96.7 97.0 97.2 95.0 93.9 91.3 
Benefit type, %          
Family 
planning 36.1 30.8 27.2 27.4 27.6 26.8 23.0 20.5 19.3 
Full Medicaid 63.9 69.2 72.8 72.6 72.4 73.2 77.0 79.5 80.7 
 
Notes: Columns may not total 100% because of rounding. 




























use disorder, % 98.2 97.9 98.0 98.0 98.1 97.9 97.8 97.8 97.8 
Substance use 
disorder*, % 1.85 2.08 2.02 1.99 1.94 2.13 2.18 2.21 2.23 
Alcohol use 
disorder 14.9 14.3 14.5 13.5 12.4 9.00 8.41 8.56 9.14 
Cannabis use 
disorder  20.8 20.2 19.5 19.4 18.4 16.6 17.6 21.4 21.7 
Opioid use 
disorder 6.99 10.0 12.6 12.9 12.5 11.8 14.9 21.0 22.6 
Other drug use 
disorder  14.5 12.1 10.2 10.7 8.21 4.02 4.53 6.43 6.50 
Polysubstance 
use disorder 42.8 43.5 43.3 43.4 48.4 58.6 54.6 42.6 40.1 
Age, %          
15-20 36.4 35.5 33.9 33.1 34.8 33.7 32.0 30.3 29.5 
21-44 63.6 64.5 66.1 66.9 65.2 66.3 68.0 69.7 70.5 
Race-ethnicity, 
%          
Non-Hispanic 
white 42.0 42.2 42.0 42.1 41.2 41.4 40.9 40.9 40.5 
Non-Hispanic 
black 52.2 51.7 51.2 51.3 51.3 50.6 50.1 48.7 48.3 
Other race-
ethnicity 5.73 6.07 6.14 6.58 7.05 7.99 9.02 8.88 9.12 
Rural/urban 
residence, %          
Rural 30.2 23.1 22.7 22.4 22.4 21.8 21.4 21.3 21.3 
Urban 69.8 76.9 67.6 77.6 77.6 78.2 78.6 78.7 78.7 
Postpartum, %          
Yes 12.5 11.8 11.7 11.2 10.8 10.2 9.47 8.70 8.95 
No 87.5 88.2 88.3 88.8 89.2 89.8 90.5 91.3 91.0 






managed care 26.9 33.6 37.0 37.6 36.9 56.7 59.2 61.3 34.3 
Fee-for-service 73.1 66.4 63.0 62.4 63.2 43.3 36.4 38.7 65.7 
Benefit type, %          
Family 
planning 16.6 15.8 17.3 19.5 19.2 21.3 18.8 19.1 18.2 
Full Medicaid 83.4 84.2 82.7 80.5 80.8 78.7 76.6 80.9 81.8 
 
Notes: Columns may not total 100% because of rounding. 






Figure S2.1. The percentage of South Carolina Medicaid-enrolled women with a substance use disorder provided a most or 


























Other drug use disorder
Polysubstance use disorder




Other drug use disorder
Polysubstance use disorder
6.5 4.5 11.9 14.5 16.2 23.7 27.9 21.3 19.1 22.0 20.8 21.8 20.0 27.0 20.8 19.7 17.1 16.4
6.0 6.0 5.8 10.8 14.6 16.6 17.1 16.4 18.1 17.4 19.5 15.8 18.4 24.5 24.1 23.0 16.3 22.8
10.9 10.1 11.3 24.8 29.2 31.9 36.7 34.6 33.3 27.1 28.6 26.8 30.4 40.8 40.5 39.6 35.7 34.5
8.5 9.3 9.2 14.6 18.5 21.1 22.7 21.0 20.0 21.7 23.4 19.9 15.8 25.4 24.9 17.6 16.7 20.1
8.2 7.4 8.3 14.1 19.4 24.6 24.7 23.7 23.9 23.3 20.3 17.2 17.5 26.9 26.1 25.6 20.7 24.6




Figure S2.2. The percentage of South Carolina Medicaid-enrolled women with a substance use disorder provided a most or 































Reported by age, % 
5.4 7.4 9.5 26.2 31.2 40.0 39.8 37.4 41.2 35.9 40.7 37.2 35.2 44.1 45.1 43.4 41.9 44.6
4.8 4.6 7.9 17.8 27.3 33.4 31.9 31.6 31.6 30.8 30.4 28.9 28.1 33.0 29.4 26.5 26.0 29.6
6.4 8.4 8.3 31.0 40.3 40.3 44.2 36.7 29.3 37.4 39.4 26.9 34.3 51.7 42.1 44.8 38.5 34.7
7.1 6.9 11.7 28.6 48.3 59.4 58.6 58.7 55.9 52.9 50.8 47.2 45.1 56.6 47.2 41.5 36.5 39.9










Figure S2.3. The percentage of South Carolina Medicaid-enrolled women with a substance use disorder provided a most or 

































Reported by age, % 
15.9 14.6 17.7 31.2 36.1 35.5 39.8 38.4 39.0 36.1 31.1 29.6 30.5 45.1 41.1 38.7 32.5 35.7
11.8 11.7 15.6 30.3 48.9 58.2 56.9 58.6 56.0 53.6 50.6 46.8 45.2 57.3 48.7 42.0 35.2 37.7
12.7 8.1 12.9 17.3 22.8 27.8 27.9 31.1 27.5 26.8 28.8 24.5 25.4 35.6 32.4 30.1 26.1 28.1
13.4 12.9 16.0 27.5 43.0 53.1 50.8 49.1 46.3 43.8 41.5 39.0 37.9 50.0 42.6 35.9 30.6 32.9










Figure S2.4. The percentage of South Carolina Medicaid-enrolled women with a substance use disorder provided a most or 





































Reported by age, % 
10.5 9.1 7.7 9.6 16.2 18.4 19.6 17.3 16.2 17.0 15.4 15.1 15.1 20.2 21.3 20.9 18.0 21.9
10.4 10.9 13.4 20.8 33.4 40.8 38.8 37.6 35.1 32.6 29.8 29.3 28.7 38.7 33.5 28.1 24.3 26.2
5.2 7.0 4.5 7.0 6.2 9.9 10.2 8.1 9.4 7.5 8.3 8.8 7.5 12.9 12.1 12.2 10.2 12.0
7.5 7.5 8.5 13.3 22.8 27.6 25.8 24.6 22.7 20.3 19.4 19.2 19.2 27.0 24.8 21.4 19.1 19.7
2.8 2.3 2.4 2.6 3.0 4.2 4.3 1.6 3.1 4.3 5.2 2.2 2.9 7.7 6.1 6.5 4.6 4.7
3.3 3.6 4.7 7.0 12.8 16.1 14.4 13.4 12.7 11.1 11.0 10.9 11.7 17.7 15.6 13.7 12.1 13.3













Figure S2.5. The percentage of South Carolina Medicaid-enrolled women with and without a substance use disorder provided 
























No SUD, non−Hispanic white
No SUD, non−Hispanic black




Reported by race−ethnicity, % 
8.1 9.3 11.1 19.4 24.8 28.3 29.8 27.5 27.7 25.9 25.5 21.1 22.4 29.1 27.5 25.1 22.0 22.8
10.7 10.7 14.0 26.0 43.1 49.5 49.1 49.0 47.2 45.0 42.7 40.2 39.4 43.3 37.0 31.7 27.7 30.6
7.8 6.1 6.1 11.3 15.6 18.8 19.8 20.4 18.4 18.6 16.9 17.9 18.6 31.2 30.7 32.4 25.2 31.0
7.9 7.6 10.6 21.3 33.7 43.3 40.8 40.0 37.7 35.1 33.5 31.6 30.6 44.5 38.3 33.4 29.0 30.4
9.7 9.1 5.3 9.7 9.5 15.6 14.2 10.6 14.5 16.7 17.0 14.7 12.0 23.7 20.4 21.3 19.6 18.9
7.8 7.7 9.8 16.9 27.0 33.5 31.1 29.4 28.0 26.8 26.4 26.1 25.7 31.1 28.6 23.9 21.5 24.0













Figure S2.6. The percentage of South Carolina Medicaid-enrolled women with and without a substance use disorder provided 



























Reported by rural−urban county of residence, % 
7.8 5.8 10.4 12.9 20.3 24.2 26.8 20.7 24.1 20.5 21.3 20.4 17.9 30.6 27.8 26.9 22.6 25.8
10.0 9.4 12.4 22.1 33.6 42.4 38.6 37.4 36.3 33.6 32.0 31.2 30.4 41.0 37.8 33.0 29.7 31.6
8.2 8.5 8.0 16.7 20.4 24.0 25.1 25.5 23.9 24.1 22.9 19.7 21.2 28.9 27.7 26.5 22.6 24.3
9.5 9.4 12.7 23.0 35.3 41.8 38.9 37.7 36.7 34.3 33.2 31.5 30.7 38.3 35.2 29.3 26.2 27.7










Figure S2.7. The percentage of South Carolina Medicaid-enrolled women with and without a substance use disorder provided 


























Reported by postpartum status, % 
23.6 24.6 27.6 41.1 46.0 44.4 48.2 46.6 45.9 46.0 45.2 42.6 45.2 55.4 56.1 54.0 50.3 52.9
25.0 25.7 34.5 50.8 53.1 59.0 57.8 57.7 57.0 57.0 54.4 53.6 50.6 61.0 60.7 53.1 49.4 59.4
3.9 4.5 5.4 10.5 15.2 19.6 19.6 18.6 19.2 17.6 17.6 15.1 15.1 22.8 20.7 20.0 16.8 18.5
6.5 6.5 9.2 19.7 35.2 43.6 41.5 40.6 38.4 35.8 34.2 32.1 31.5 40.7 34.3 29.6 25.8 27.6










Figure S2.8. The percentage of South Carolina Medicaid-enrolled women with and without a substance use disorder provided 


























Reported by health plan type, % 
6.2 0.0 6.1 14.7 18.3 7.8 21.1 23.7 18.9 20.7 22.0 18.7 19.0 26.4 27.2 26.3 22.4 24.6
5.0 5.5 9.1 16.6 19.5 16.6 21.6 20.7 21.9 27.5 27.6 26.8 26.0 31.6 32.4 29.9 28.4 30.7
8.2 8.0 8.6 15.6 20.4 24.5 25.7 24.2 24.2 23.8 22.5 20.5 21.4 31.3 28.6 27.4 22.9 24.1
9.2 9.1 12.3 24.0 39.1 48.3 46.9 45.7 44.0 44.0 42.7 41.2 40.8 53.8 52.2 44.0 37.8 40.9










Figure S2.9. The percentage of South Carolina Medicaid-enrolled women with and without a substance use disorder provided 






















No SUD, family planning
No SUD, full Medicaid
SUD, family planning
SUD, full Medicaid
Reported by benefit type, % 
13.2 16.4 13.9 20.8 30.9 32.2 38.6 31.1 29.1 31.9 29.1 22.6 30.9 45.3 36.4 33.6 26.4 27.1
8.3 9.0 12.3 25.9 51.5 65.3 61.4 61.4 58.9 55.7 54.5 49.3 47.4 63.5 53.4 42.1 34.3 33.4
7.6 6.6 7.9 14.9 19.1 22.9 24.1 23.4 23.5 22.4 22.2 19.6 19.7 27.6 26.8 25.7 22.1 24.2
10.4 9.6 12.7 21.5 28.4 33.4 32.1 31.5 31.2 29.8 28.8 27.7 26.6 33.0 30.9 27.2 25.2 27.4










Figure S2.10. The percentage of South Carolina Medicaid-enrolled women with a substance use disorder provided a long-


























Other drug use disorder
Polysubstance use disorder




Other drug use disorder
Polysubstance use disorder
0.00 0.00 0.00 0.00 1.35 1.32 0.90 0.93 2.04 1.61 1.58 3.48 2.37 2.63 2.57 2.55 2.65 2.50
0.26 0.00 0.00 0.00 0.69 0.26 0.26 1.08 2.33 1.77 2.88 2.02 1.64 4.19 3.38 4.99 1.34 5.32
0.37 0.32 0.48 1.44 1.30 0.41 1.76 1.45 4.53 3.43 4.08 3.60 4.86 6.56 8.13 10.90 7.34 8.07
0.37 0.00 0.24 0.74 0.50 0.39 0.94 1.29 2.27 3.10 4.46 2.02 1.04 3.01 5.41 3.52 5.06 2.69
0.18 0.19 0.00 0.59 1.03 0.85 1.07 1.14 2.70 3.08 2.40 2.77 2.82 3.74 3.71 4.98 4.13 5.73




Figure S2.11. The percentage of South Carolina Medicaid-enrolled women with a substance use disorder provided a long-































Reported by age, % 
0.00 0.00 0.00 0.64 0.56 0.00 0.27 1.24 1.99 1.38 3.44 3.80 3.29 6.10 5.87 6.53 6.86 6.28
0.03 0.08 0.06 0.09 0.13 0.18 0.27 0.66 1.38 1.58 1.59 1.74 2.09 2.29 2.53 2.71 2.71 3.02
0.00 1.05 0.92 3.54 3.36 0.00 5.45 2.88 4.88 9.89 9.09 8.24 8.70 13.27 10.36 12.39 10.76 12.65
0.32 0.46 0.51 0.71 0.73 1.03 1.51 3.24 5.20 5.31 5.15 5.48 5.70 5.48 5.72 5.71 4.84 5.32










Figure S2.12. The percentage of South Carolina Medicaid-enrolled women with a substance use disorder provided a long-


































Reported by age, % 
0.6 0.6 0.4 2.0 2.1 1.4 2.4 2.9 6.3 4.7 4.6 5.6 5.9 6.8 7.8 10.2 6.9 9.6
0.6 0.6 0.8 0.9 1.1 1.5 1.7 3.8 5.8 5.6 5.1 5.5 6.2 6.1 6.9 6.6 5.6 6.6
1.0 0.0 0.3 0.3 0.3 1.4 0.2 1.6 3.9 3.1 4.5 2.6 2.7 4.7 5.2 6.1 5.3 6.7
0.6 0.6 0.7 0.8 0.9 1.3 1.6 2.6 4.0 4.0 3.4 4.0 4.2 4.7 5.2 5.2 4.2 5.3










Figure S2.13. The percentage of South Carolina Medicaid-enrolled women with a substance use disorder provided a long-





































Reported by age, % 
0.4 0.0 0.0 0.0 0.9 0.9 0.8 0.6 3.2 2.4 1.4 1.8 2.1 2.2 2.8 4.0 3.3 3.8
0.3 0.4 0.4 0.5 0.6 0.9 1.2 1.8 2.2 2.4 2.1 2.5 2.7 3.0 3.1 2.9 2.8 3.5
0.0 0.0 0.0 0.0 0.9 0.0 0.3 0.0 0.3 1.0 0.4 1.5 0.7 1.2 1.1 2.2 0.9 1.9
0.3 0.3 0.4 0.4 0.4 0.6 0.7 1.0 1.3 1.4 1.2 1.7 2.0 1.7 2.2 2.1 2.1 2.3
0.0 0.0 0.0 0.3 0.0 0.0 0.3 0.0 0.6 0.6 1.0 0.5 0.0 0.4 0.4 0.8 0.4 0.8
0.1 0.2 0.2 0.2 0.2 0.2 0.3 0.5 0.6 0.5 0.8 0.9 1.0 1.1 1.1 1.1 1.0 1.4













Figure S2.14. The percentage of South Carolina Medicaid-enrolled women with and without a substance use disorder provided 























No SUD, non−Hispanic white
No SUD, non−Hispanic black




Reported by race−ethnicity, % 
0.47 0.26 0.29 1.08 1.13 0.72 1.32 1.43 3.39 3.31 3.24 2.91 2.98 4.09 4.15 5.46 4.33 4.83
0.52 0.59 0.69 0.85 0.89 1.15 1.44 2.81 4.07 3.88 3.61 3.86 4.30 4.22 4.55 4.33 3.65 4.46
0.14 0.00 0.00 0.13 0.81 0.26 0.42 1.07 2.41 2.58 2.79 2.63 3.13 4.60 5.49 6.72 3.98 6.88
0.24 0.27 0.31 0.35 0.46 0.70 0.90 1.73 2.75 2.97 2.69 3.17 3.43 3.57 3.93 3.96 3.53 3.90
0.00 0.00 0.00 0.00 0.00 0.65 1.14 0.00 1.08 1.01 1.66 3.19 1.03 3.62 2.99 3.60 5.96 4.10
0.65 0.66 0.67 0.64 0.89 1.06 1.40 1.80 2.99 2.66 2.68 2.95 3.56 3.42 4.08 3.69 3.31 4.04













Figure S2.15. The percentage of South Carolina Medicaid-enrolled women with and without a substance use disorder provided 



























Reported by rural−urban county of residence, % 
0.30 0.00 0.00 0.17 1.35 0.33 1.35 0.50 3.45 1.71 0.80 1.88 2.01 3.30 3.55 4.83 4.30 4.35
0.35 0.40 0.46 0.57 0.72 0.99 1.12 1.89 3.03 3.06 2.37 2.72 2.84 2.87 3.41 3.56 3.08 3.65
0.26 0.16 0.20 0.82 0.76 0.64 0.91 1.49 2.73 3.38 3.55 3.08 3.04 4.40 4.60 5.78 4.36 5.51
0.41 0.46 0.52 0.61 0.69 0.94 1.27 2.55 3.76 3.76 3.51 3.82 4.15 4.07 4.34 4.19 3.66 4.25










Figure S2.16. The percentage of South Carolina Medicaid-enrolled women with and without a substance use disorder provided 




























Reported by postpartum status, % 
1.24 0.75 0.68 2.04 3.83 1.31 3.56 3.28 8.64 9.98 9.38 8.13 9.18 12.03 14.05 16.44 14.33 19.53
1.29 1.53 1.95 2.42 2.99 3.65 4.40 9.14 12.90 14.15 12.24 13.18 13.68 13.40 16.84 15.85 13.72 16.67
0.00 0.00 0.06 0.35 0.35 0.39 0.38 0.70 1.70 1.24 1.68 1.76 1.48 2.24 2.00 2.97 2.26 2.28
0.22 0.26 0.29 0.35 0.35 0.54 0.64 1.04 1.78 1.76 1.82 2.13 2.52 2.65 2.77 2.88 2.64 2.98










Figure S2.17. The percentage of South Carolina Medicaid-enrolled women with and without a substance use disorder provided 



























Reported by health plan type, % 
0.00 0.00 2.04 0.00 0.00 0.00 0.00 1.28 1.14 2.60 3.45 2.76 2.63 3.09 3.62 5.43 4.30 4.66
0.22 0.34 0.28 0.13 0.40 0.51 0.84 1.40 2.10 3.71 3.63 3.88 4.16 3.86 4.39 4.39 3.91 4.57
0.27 0.13 0.10 0.65 0.95 0.57 1.09 1.21 3.04 2.96 2.68 2.90 2.95 5.00 5.91 5.99 4.38 7.06
0.38 0.42 0.49 0.60 0.68 0.96 1.21 2.28 3.51 3.27 2.87 3.34 3.81 4.15 4.95 4.87 4.47 5.19










Figure S2.18. The percentage of South Carolina Medicaid-enrolled women with and without a substance use disorder provided 
























No SUD, family planning
No SUD, full Medicaid
SUD, family planning
SUD, full Medicaid
Reported by health plan type, % 
0.00 0.00 0.48 0.47 2.42 0.50 1.72 0.51 4.23 6.67 4.69 3.29 4.42 6.29 7.42 8.26 5.75 5.69
0.30 0.48 0.53 0.57 0.64 0.91 1.18 2.44 3.25 3.44 3.06 3.52 4.04 4.44 4.61 4.57 3.85 4.45
0.30 0.14 0.11 0.66 0.77 0.57 0.97 1.31 2.79 2.62 2.90 2.81 2.72 4.00 4.02 5.28 4.17 5.25
0.43 0.42 0.48 0.60 0.72 0.97 1.25 2.32 3.61 3.58 3.28 3.59 3.82 3.65 4.01 3.93 3.46 4.05










PATTERNS IN POSTPARTUM CONTRACEPTIVE INITIATION AMONG 
REPRODUCTIVE-AGE WOMEN WITH AND WITHOUT OPIOID USE DISORDERS: 




Background: Non-postpartum women with opioid use disorder (OUD) and other substance use 
disorders (SUD) report a lower prevalence of contraceptive use than non-substance-using 
women. Limited research has examined whether this extends to women in the postpartum period. 
Moreover, no studies have assessed differences in the postpartum contraception behaviors of 
women with OUD and women with non-opioid SUD.  
Objective: To investigate patterns in postpartum contraceptive initiation among women with 
OUD, women with non-opioid SUD, and women without SUD. 
Methods: This retrospective cohort study included South Carolina Medicaid-enrolled 
women aged 15-44 who had singleton live birth between January 2005 to June 2017. We 
identified the study sample and variables using common diagnostic, procedural, and drug code 
sets. We used multivariable logistic regression and inverse probability of treatment weighting 
analyses to estimate the relationship between OUD and contraceptive initiation in the immediate 
postpartum period and at 3, 6, and 12 months postpartum.  
Results: There were 23,326 live birth deliveries from 2005 to mid-2017. The total number of 
women with a SUD was 1,622, including 244 women with an OUD and 1,378 women with a 
non-opioid SUD. The prevalence of postpartum contraceptive initiation at 12 months after 
delivery was lower for women with OUD than women with non-opioid SUD and women without 
SUD (63.2% vs 66.4% and 71.1%). Compared to women with OUD, women without SUD had 
higher odds of initiating most or moderately effective contraceptive methods than no method by 
3, 6, and 12 months postpartum in multivariable (3 months: adjusted odds ratios [aOR] 1.71, 
95% CI 1.31-2.24; 6 months: aOR 1.72, 95% CI 1.31-2.25; 12 months: aOR 1.84, 95% CI 1.40-
2.43) and weighted (3 months: aOR 1.63, 95% CI 1.24-2.15; 6 months: aOR 1.51, 95% CI 1.12-
 68 
2.03; 12 months: aOR 1.60, 95% CI 1.20-2.14) regression models. In multivariable models, 
women with non-opioid SUD had higher odds of initiating most or moderately effective 
contraceptive methods than no method by 3 months (aOR 1.34, 95% CI 1.01-1.78) and 12 
months (aOR 1.37, 95% CI 1.02-1.84) postpartum. Multivariable models also showed that 
women without SUD had higher odds of initiating most effective contraceptive methods than 
moderately effective methods or no method at 12 months postpartum compared to women with 
OUD (aOR 1.34, 95% CI 1.01-1.78). 
Conclusion: OUD may be associated with decreased use of most and moderately effective 
contraceptive methods in the postpartum period. More research is needed to understand the 




Among women with substance use disorders (SUD), more than 7 out of every 10 
pregnancies are unintended.1–5 Unintended pregnancy is associated with unfavorable 
maternal and perinatal health behaviors and outcomes, such as delayed prenatal care 
initiation, maternal anxiety and depression, and low birth weight.6,7 Many factors, such as 
limited contraceptive access and inconsistent contraceptive use, are thought to play a role 
in the high rates of unintended pregnancy in the United States (US).8 
Several studies conducted in samples of non-pregnant, non-postpartum women 
indicate that women with SUD use contraceptives less often, and use less effective 
methods, than women without SUD.4,5,9–11 Whether this extends to women in the 
postpartum period is not well known. Only one recent study, to our knowledge, has 
examined the postpartum contraceptive behaviors of women with SUD while using a 
comparison group of women without SUD. In a study by MacAfee and colleagues, 
women reporting drug use during pregnancy were significantly less likely to use 
contraception in the postpartum period than women who did not report prenatal drug use 
(79.6% vs 88.1%).12 Pregnancy is considered a ‘window of opportunity’ and may provide 
an optimal time to improve long-term maternal and child health through providing access 
to care and planning for future pregnancies.   
Prior US investigations of postpartum contraceptive behaviors of women with 
SUD have largely been restricted to women with opioid use disorders (OUD). In these 
studies, use of highly effective or effective methods by 3 months postpartum ranged from 
25.5%-62%.13–15 In the sole study examining postpartum contraceptive use in a sample of 
 70 
women reporting risky use of other substances, 71.3% of study participants reported 
using contraceptives at 3 months postpartum,3 which is higher than prevalence rates 
reported in studies restricted to opioid-using populations and appears to be closer in line 
with the findings reported by MacAfee et al.  
Because women with OUD may differ from women with non-opioid SUD (e.g. 
cocaine use disorder, methamphetamine use disorder) and women without SUD in 
several important ways, including their sociodemographics, medical and mental health 
comorbidities, and treatment needs and outcomes,16,17 it is plausible that the postpartum 
contraceptive behaviors of women with OUD are different than those of women with 
non-opioid SUD and women without SUD. However, based on existing research, it 
remains unclear whether such differences exist. This study compared patterns of 
postpartum contraceptive initiation among women with OUD, women with non-opioid 
SUD, and women without SUD. We conducted this research to offer support for 
clinicians providing reproductive health services to substance-using women of 
childbearing age. Knowledge gained from this study may inform tailoring of 
contraceptive counseling and provision for patients with OUD. 
METHODS 
Data and study population 
We conducted a retrospective analysis of de-identified South Carolina (SC) 
Medicaid claims data requested from the SC Office of Research and Statistics. These data 
include detailed information about medical and pharmacy dispensing claims, as well as 
patient demographic and enrollment data, for Medicaid beneficiaries during eligible 
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periods. The Clemson University Institutional Review Board deemed this study exempt 
from review. 
The study cohort was selected from a database of women aged 15-44 years who 
were enrolled in SC Medicaid between January 2000 and June 2018. From this source 
population, we identified women who had at least one live birth delivery with continuous 
enrollment from 60 months prior to delivery through 12 months postpartum. Restricting 
the sample to women with continuous enrollment for 5 years before delivery allowed us 
to ascertain important pre-pregnancy covariates, such as past contraceptive use, that are 
highly correlated with postpartum contraceptive initiation. Similar to previously validated 
methods,18 we identified live birth deliveries using diagnosis-related groups, 
International Classification of Diseases, Ninth and Tenth Revisions (ICD-9 and ICD-10) 
diagnosis and procedure codes, and Healthcare Common Procedure Coding System 
(HCPCS) codes (Appendix D). We excluded births from twin or higher-order 
pregnancies because contraceptive provision and use may differ for women with multiple 
and singleton gestations. We further excluded deliveries that occurred in 2000-2004 or 
after June 2017 because complete data were not available for these women. Of the 
remaining births, only the first delivery for each woman was used in the analysis. 
Exposure 
Our exposure variable was SUD, defined as a diagnosis of alcohol or drug abuse 
or dependence in the 5 years prior to delivery. We did not include tobacco in our 
definition because it is poorly captured in administrative data.19 Women with SUD were 
identified on the basis of ICD-9 or ICD-10 diagnosis codes in any position on >1 
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inpatient or >2 outpatient or professional claims on different service dates (Appendix 
A).20 We further identified women with SUD by searching medical and pharmacy claims 
using HCPCS codes and National Drug Code (NDC) numbers for medications used treat 
alcohol and opioid use.21 Because our primary interest was to examine differences in 
postpartum contraceptive behaviors of women with and without OUD, we stratified 
women without OUD into two groups, including women with non-opioid SUD and 
women without SUD.  
Outcomes 
Outcomes included contraceptive initiation within the immediate postpartum 
period and by 3, 6, and 12 months postpartum. From inpatient, outpatient, and 
professional claims using ICD-9 and ICD-10 diagnosis and procedure codes, HCPCS 
codes, and NDC codes (Appendix B codes), we identified the following contraceptive 
methods: female sterilization, implants, intrauterine devices or systems (IUD/IUS), 
injectables, oral pills, patch, ring, and diaphragm. We were unable to examine over-the-
counter or no cost contraceptive methods, such as condoms, sponge, spermicide, 
withdrawal, or natural family planning, that are not reimbursed by Medicaid. On the basis 
of the NQF-endorsed performance measures,22 we categorized methods into most 
effective (sterilization, implants, and IUD/IUS) and moderately effective (injectables, 
oral pills, patch, ring, and diaphragm). Women who were not using one of these methods 
were classified as using no method, although they may have been using a non-
prescription or no cost method. If women used more than one method within the 12-
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month postpartum period, the first method initiated was used in the analysis given that 
our objective was to examine initiation and not discontinuation.  
Covariates 
We a priori selected several demographic, pregnancy and reproductive health, and 
medical covariates because of their potential association with SUD or postpartum 
contraceptive initiation. These included age, race-ethnicity, marital status, county of 
residence, plan type at delivery, year of delivery, number of prenatal care visits, 
postpartum visit attendance, parity, past contraceptive use, and medical covariates. We 
coded missing values of marital status as a separate category because this variable 
contained a high percentage of missing data (27.5%).23,24 Using the US Department of 
Agriculture’s 2013 Urban Influence Codes, we designated county of residence as 
metropolitan (urban) or non-metropolitan (rural) (Appendix C).25 Plan type at delivery 
included fee-for-service (FFS) or Medicaid managed care (MMC). Because of the high 
correlation between parity and postpartum contraceptive use, we created a modified 
parity variable based on the methodology from a previous study.13 Women with >1 
pregnancies in the 5 years prior to delivery were classified as having >2 pregnancies. For 
these women, we defined the outcome of the previous pregnancy, including live birth or 
non-live birth (miscarriage, ectopic pregnancy, induced abortion, or stillbirth), using 
ICD-9 and ICD-10 diagnosis codes and HCPCS codes (Appendix B). We also created a 
variable to adjust for past contraceptive use, which was categorized into a most effective 
reversible methods, moderately effective methods, or no method.22 If women used more 
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than one contraceptive method in the years preceding delivery then the most recently 
used method was selected.  
For medical covariates, we created indicators for mental health comorbidities and 
22 chronic conditions (breast cancer, malabsorptive bariatric surgery, venous 
thromboembolism, valvular heart disease, systematic lupus erythematosus, liver cancer, 
severe liver cirrhosis, ischemic heart disease, chronic hypertension, stroke, migraine with 
aura, diabetes with and without complications, peripartum cardiomyopathy, malignant 
gestational trophoblastic disease, epilepsy, ovarian cancer, endometrial cancer, 
thrombogenic mutations, tuberculosis, sickle cell disease, schistosomiasis with fibrosis of 
liver, and solid organ transplantation) that have been identified by the Centers for Disease 
Control and Prevention (CDC) as US Medical Eligibility for Contraceptive Use.26 
Conditions were defined as having a HCPCS code for the condition, or an ICD-9 or ICD-
10 diagnosis or procedure code for the condition in any field, on >1 inpatient or >2 
outpatient or professional claims at least 30 days apart in the two years prior to delivery 
(Appendix E).27 Exceptions included bariatric surgery and organ transplant, which only 
needed one outpatient claim, and breast cancer, which was observed in the 5 years prior 
to delivery.26   
Statistical analysis 
We summarized the distribution of covariates across women with OUD, women 
with non-opioid SUD, and women without SUD using univariate and bivariate statistics. 
Categorical variables were compared using chi-square tests. To compare contraceptive 
initiation within the immediate postpartum period and by 3, 6, and 12 months postpartum 
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among women with and without OUD, we constructed multivariable models adjusted for 
all demographic, pregnancy and reproductive health, and medical covariates. Separate 
models estimated adjusted odds ratios (OR) and 95% confidence intervals (CI) for two 
binary outcomes: initiation of most or moderately effective methods vs no method and 
initiation of most effective methods vs moderately effective methods or no method.  
In addition to traditional covariate adjustment, we applied propensity score (PS) 
weighting to balance women with OUD, women with non-opioid SUD, and women 
without SUD on baseline covariates. We used inverse probability of treatment weighting 
(IPTW), which is one application of PS weighting that uses the PS to form a weight for 
each individual in the sample, to determine the average treatment effect on the treated 
(ATT). When estimating ATT, the weight equals 1 for subjects in the treatment group 
and the odds of receiving the treatment for subjects in the control group.28 In this study, 
women with OUD received a weight of 1 while women in the comparison groups 
received a weight equal to the odds of having an OUD. This technique allowed us to 
estimate the effect of having an OUD on postpartum contraceptive initiation for women 
with non-opioid SUD and women without SUD. 
To generate propensity scores and associated weights, we used the Toolkit for 
Weighting and Analysis of Nonequivalent Groups (twang) package, as implemented 
through SAS twang macros.29 This program uses generalized boosted models to estimate 
PS weights and incorporates various diagnostic checks to assess the quality of weights 
and balance of baseline covariates before and after weighting. A detailed description of 
the methods used in this tool has been published elsewhere.29,30  
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Our PS models included all previously described demographic, pregnancy and 
reproductive health, and medical covariates. We assessed covariate balance between 
women with OUD and women in the comparison groups by calculating the difference in 
means in units of the pooled standard deviation,31 or standardized difference, for each 
covariate before and after PS weighting. The common threshold of <.10 was selected to 
indicate an acceptable balance between groups.32 We evaluated the relationship between 
OUD and postpartum contraceptive initiation using weighted logistic regression models. 
As a final step, we calculated predicted probabilities of each outcome from weighted 
regression models and tested for statistically significant differences. 
To evaluate the robustness of our findings, we conducted several additional 
analyses.  First, to explore how using an altered sample selection criteria would impact 
the estimates, we analyzed the data with a new study cohort that included women with 36 
months of continuous Medicaid enrollment before delivery. While this resulted in more 
women in the analytic sample, the trade-off was that we were unable to examine parity 
and past contraceptive use prior to 3 years before delivery. Second, to ensure that 
including missing values as a category in the marital status variable did not affect the 
estimates, we performed complete case analysis. Third, we ran analyses with a restricted 
exposure definition, which included receiving a SUD diagnosis in the 2 years prior to 
delivery, to assess how a different exposure window would impact the precision of the 
results. Third, in the subgroups of women with SUD, we repeated the main analysis while 
additionally adjusting for polysubstance use disorder (PSUD) (yes vs no) to eliminate the 
possibility that polysubstance use was responsible for the observed effects. Data were 
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analyzed with SAS version 9.4 (SAS institute Inc., Cary, NC) and Stata version 14.1 
(StataCorp).  
RESULTS 
The final study cohort included 23,326 women aged 15-44 years who had a 
singleton live birth covered by South Carolina Medicaid between January 2005 and June 
2017 and who met the continuous enrollment criteria (Figure 3.1).  Of these women, 
SUD diagnoses were present in 1,622 (6.95%) women, including 244 (1.05%) with OUD 
and 1,378 (5.91%) with non-opioid SUD. At baseline, women with OUD more likely to 
be older, white, and have MMC, >2 pregnancies prior to delivery, and mental health 
comorbidities (P<.05 across all comparisons) than women with non-opioid SUD and 
women without SUD (Table S3.1). In the weighted sample, the distribution of baseline 
covariates between women with OUD and control groups were similar on the basis of 
standardized differences <.10 (Table 3.1).  
Before weighting, there were significant differences between women with OUD 
and women without SUD in the prevalence of postpartum contraceptive use across all 
time points (Table 3.2). No significant differences were observed in rates of postpartum 
contraceptive initiation between women with OUD and women with non-opioid SUD. 
Compared to other women, women with OUD were more likely to receive female 
sterilization or implants and less likely to receive IUD/IUS, oral pills, or patch in the 
postpartum period (Table S3.2). After weighting, significant differences remained 
between women with OUD and women without SUD in initiation of most or moderately 
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effective contraceptive methods by 3, 6, and 12 months postpartum (P<.05 for all 
comparisons) (Table 3.2).  
Multivariable models showed that women with non-opioid SUD and women 
without SUD had significantly greater odds of initiating postpartum contraception of 
most or moderately effective methods vs no method by 3 months (Non-opioid SUD: aOR 
1.34, 95% CI 1.01-1.78); No SUD: aOR 1.71, 95% CI 1.31-2.24) and 12 months (Non-
opioid SUD: aOR 1.37, 95% CI 1.02-1.84); No SUD: aOR 1.84, 95% CI 1.40-2.43) 
postpartum than women with OUD (Table 3). This relationship was also significant for 
the 6 month time point for women without SUD (aOR 1.72, 95% CI 1.31-2.25). 
Moreover, women without SUD had higher odds of initiating most effective 
contraceptive methods vs moderately effective methods or no method by 12 months 
postpartum compared to women with OUD (aOR 1.34, 95% CI 1.01-1.78).   
In weighted regression models, women without SUD compared to women with 
OUD had significantly greater odds of initiating most or moderately effective 
contraceptive methods vs no method within 3 months (aOR 1.63, 95% CI 1.24-2.15), 6 
months ( aOR 1.51, 95% CI 1.12-2.03), and 12 months (aOR 1.60, 95% CI 1.20-2.14) 
postpartum (Table 3.3). Among women with non-opioid SUD, none of the observed 
associations attained statistical significance. Moreover, none of the results for the second 
outcome of interest were statistically significant. In line with regression estimates, 
predicted probabilities of initiating most or moderately effective contraceptive methods 
by 3, 6, and 12 months postpartum were significantly greater for women without SUD 
than women with OUD (P<.01 for all comparisons) (Figure 3.2). Predicted probabilities 
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of initiating most effective contraceptive methods vs moderately effective methods or no 
method were not significant for any of the observed time points (Figure 3.3). 
When data were analyzed using alternate sample selection criteria, the magnitude 
of associations were smaller than those observed in the main analysis (Table S3.3). 
However, results remained statistically significant. Women without SUD had 
significantly higher odds of initiating most or moderately effective methods by 3 months 
(aOR 1.47, 95% CI 1.21-1.77), 6 months ( aOR 1.42, 95% CI 1.18-1.72), and 12 months 
(aOR 1.48, 95% CI 1.22-1.81) postpartum in comparison to women with OUD. Complete 
case analysis produced slightly stronger point estimates than the main analysis (Table 
S3.4). More associations were statistically significant in analyses that used a restricted 
exposure definition (Table S3.5). Both comparison groups had higher odds of initiating 
most effective methods vs moderately effective methods or no method within 3 months 
(Non-opioid SUD: aOR 1.65, 95% CI 1.06-2.56); No SUD: aOR 1.65, 95% CI 1.10-2.50) 
and 12 months (Non-opioid SUD: aOR 1.54, 95% CI 1.01-2.34); No SUD: aOR 1.63, 
95% CI 1.10-2.41) postpartum than women with OUD. Adjusting for PSUD in the 
subgroup of women with SUD strengthened the magnitude of the observed associations. 
Results of both outcomes for the 12-month time point reached statistical significance in 
multivariable models (Most or moderate vs no method: aOR 1.40, 95% CI 1.01-1.95; 
Most vs moderate or no method: aOR 1.44, 95% CI 1.03-2.03) (Table S3.6). 
DISCUSSION  
 In this retrospective cohort analysis, we found that women with OUD were less likely 
than women without OUD, including women with non-opioid SUD and women without 
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SUD, to initiate most or moderately effective contraceptive methods within the extended 
postpartum period. OUD was not associated with decreased contraceptive use in the 
immediate postpartum period. The directions of associations were similar in 
multivariable and weighted logistic regression models. However, PS weighting 
attenuated the magnitude of the observed associations and only the results for comparison 
group women without SUD remained statistically significant in the main analysis.  
 Supplemental analyses demonstrated that associations between OUD and 
decreased contraceptive initiation were robust to altered sample selection criteria, a 
narrower exposure definition, and a different model specification. The results were 
similar in a larger sample of women with fewer years of continuous enrollment. Because 
relatively few women remain continuously enrolled in Medicaid for 5 years, these 
findings may be generalizable to a broader set of women with SUD.  Of note, many of 
the observed associations reached statistical significance when SUD was defined as 
receiving a diagnosis in the 2 years instead of 5 years before delivery. This suggests that 
the postpartum contraceptive behaviors of women with OUD may be influenced by their 
stage of addiction and treatment. 
Our study builds on research examining postpartum contraceptive use in women 
with SUD. Consistent with other reports,14,15 we found that 51.6% of women with OUD 
initiated most or moderately effective contraceptive methods by 3 months postpartum, 
which is double that of Pennsylvania Medicaid-enrolled women with OUD (25.5%).13 
Our data also show that 30.7% of women with OUD obtained female sterilization or 
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LARC methods by 3 months postpartum, which is substantially higher than the 7.4% 
reported among Pennsylvania Medicaid-enrolled women.13  
Only one US study has examined contraceptive outcomes among women with 
SUD past 90 days postpartum. In that study, two-thirds of participants reported using any 
contraceptive method at 12 months.3 We found similar rates of use of most or moderately 
effective methods for women with OUD (63.2%) and women with non-opioid SUD 
(66.4%) by 12 months postpartum. However, there were notable differences in the types 
of methods reported. In our sample, fewer women received injectables or IUD/IUS and 
more women received oral pills.        
Similar to McAfee et al,12 we found that women without SUD were more likely to 
use contraceptives in the postpartum period than women with SUD, specifically women 
with OUD. Though, prevalence rates of most or moderately effective contraceptive use 
by 3 months postpartum were lower among women in our sample. Our results are likely 
underestimated given our data source and inability to examine contraceptive methods that 
are not reimbursed by Medicaid. 
Any combination of patient or provider factors could explain these findings. Some 
women with OUD have a low perceived risk of pregnancy due to past infertility, 
menstrual irregularities, or low libido associated with opioid use33,34 and consequently 
could be disinclined to initiate postpartum contraception. Moreover, women with OUD 
may experience ambivalence towards pregnancy or preventing pregnancy,1 which could 
contribute to a lack of motivation in starting or continuing contraceptives. Even in the 
absence of pregnancy ambivalence, women with OUD may find it difficult to take a 
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proactive approach to preventing pregnancy34 or desire pregnancy as a means of 
achieving sobriety or accessing treatment.35,36 Alternatively, women with non-opioid 
SUD may have a stronger desire than women using prescription opioids to delay or 
prevent future pregnancies due to homelessness, social instability, or risky life situations. 
It is also possible that providers tailor discussions around contraceptive methods 
differently for women with alcohol use disorder because of the teratogenic potential of 
alcohol or for women with SUD who use illicit substances rather than prescription drugs 
such as opioids. 
This study should be replicated with other state or national data to establish 
generalizability. If the results reported here hold in future studies, they would have 
important implications for clinical research and practice. Women with OUD commonly 
experience personal, interpersonal, and systems-level barriers to contraceptive uptake and 
continued use.2,10,37 Developing and evaluating innovative strategies aimed at increasing 
family planning access and services for women with OUD who desire pregnancy 
prevention is an important area for future research. Providers should be aware that 
women with OUD may be less inclined to use contraceptives than non-opioid substance 
using patients or patients without SUD and provide family planning counseling and 
education accordingly. In the meantime, providers should aim to foster trust with all 
patients with SUD by providing empathetic, compassionate family planning care using a 
patient-centered approach. 
Strengths and limitations 
This study has several strengths. Previous studies examining postpartum 
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contraceptive use among women with SUD have been limited by their lack of 
comparison populations.9 We created two similar comparison groups for women with 
OUD by using statistical methods for causal inference. Our analysis also accounted for 
past medical and reproductive health factors that could influence postpartum 
contraceptive initiation. However, we were unable to account for events that occurred 
outside of this period, such as LARC insertion or sterilization, which may have impacted 
the study findings. In addition, we present a novel finding of the role of SUD type on 
postpartum contraceptive use outcomes. 
This study also has limitations. Findings may not be generalizable to Medicaid-
enrolled women in other states, women with private or no insurance, or women with non-
continuous Medicaid enrollment. This study is subject to limitations of claims data, 
including coding inaccuracies or missing data, misclassification bias, and reliance on 
health conditions that are captured in the administrative billing records. Substance use, in 
particular, is prone to misclassification and under-reporting because it requires that 
providers uncover or patients disclose sensitive or illicit behaviors. However, any 
misclassification of women with SUD as non-users in this study would likely bias our 
findings toward the null. Finally, as with any observational study design, we could not 
completely eliminate residual confounding from unobserved factors. 
CONCLUSION 
Current evidence supports that women with OUD face extensive barriers to 
contraceptive use, but more research is needed to understand the patient and provider 
factors that are associated with the findings presented herein. In particular, the differential 
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contraceptive behaviors of women with OUD and women with non-opioid SUD merit 
further study. Future research should also examine the extent to which OUD is associated 
with higher rates of postpartum contraceptive non-adherence and discontinuation. 
Ensuring that women with OUD and other SUD have equitable access to family planning 
services and counseling is critical for advancing the health of mothers and babies and 
increases the likelihood of lifelong positive outcomes. For women with SUD who desire 
pregnancy prevention, new and innovative strategies that optimize family planning 
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Table 3.1. Demographic, pregnancy and reproductive health, and medical covariates of South Carolina Medicaid-enrolled 







(n=21,704) Absolute Standardized Differences 
Covariates n (%) n (%) n (%) Before weighting After weighting 
Demographic       
Age group (years)    .67 .03 
15-19 35 (14.3) 34.3 (15.8) 37.2 (15.7)    
20-24 50 (20.5) 42.6 (19.6) 48.3 (20.4)   
25-34 139 (57.0) 120.8 (55.7) 131.9 (55.6)   
35-44 20 (8.20) 19.2 (8.86) 19.8 (8.35)   
Race    .59 .008 
Non-Hispanic white 198 (82.5) 175.3 (81.6)  190.9 (81.8)   
Non-Hispanic black 26 (10.8) 27.2 (12.7)  28.9 (12.4)    
Hispanic/Latino 2 (0.83) 1.01 (0.47) 1.09 (0.47)   
Other race-ethnicity* 14 (5.83) 11.2 (5.24)  12.6 (5.41)    
Marital status    .08 .02 
Single 145 (59.4) 126.3 (58.2)  139.7 (58.9)    
Married 10  (4.10) 11.1 (5.10)  12.0 (5.04)   
Not married or separated 5  (2.05) 5.71 (2.63)  4.59 (1.94)    
Unknown 18 (7.38) 13.3 (6.13)   16.6 (7.00)    
Missing 66 (27.1) 60.5 (27.9) 64.3 (27.1)   
County of residence†    .13 .07 
Rural 69 (29.2) 54.8 (26.1) 64.8 (28.1)   
Urban 167 (70.8) 155.5 (73.9)  165.5 (71.9)    
Pregnancy and reproductive health      
Plan type    .36 .03 
Medicaid managed care 167 (68.4) 147.9 (68.2)  158.6 (66.9)    
Fee-for-service 77 (31.6) 69.1 (31.8)  78.5 (33.1)    
Year of delivery    .54 .04 
2005 17 (6.97) 13.8 (6.34) 14.6 (6.18)    
2006 5  (2.05) 7.87 (3.62)  9.05 (3.82)    
2007 20 (8.20) 18.3 (8.42) 18.4 (7.77)    
2008 17 (6.97) 13.1 (6.05)  13.9 (5.87)    
2009 14 (5.74) 12.2 (5.61)  13.8 (5.84)    

































OUD, opioid use disorder; Non-opioid SUD, non-opioid substance use disorder; SUD, substance use disorder. 
Percentages may not add to 100% due to rounding. 
* Includes Asian, Native American, and more than one race-ethnicity. 
† Derived using the United States Department of Agriculture’s Urban Influence Codes. 
‡ Within 3 months following delivery. 
§ Based on claims in the 5 years prior to delivery. 
2011 11 (4.51) 9.85 (4.54)  9.92 (4.18)    
2012 14 (5.74) 13.6 (6.26)  12.1 (5.09)    
2013 16 (6.56) 11.4 (5.28)  17.2 (7.24)    
2014 22 (9.02) 21.3 (9.82)  23.1 (9.74)    
2015 38 (15.6) 34.3 (15.8)  33.4 (14.1)    
2016 43 (17.6) 35.7 (16.5)  43.6 (18.4)   
2017 18 (7.38) 13.6 (6.25) 16.0 (6.74)   
Number of prenatal visits    .05 .04 
0-1 62 (25.4) 56.8 (26.2)  63.7 (26.8)   
2-3 62 (25.4) 45.6 (21.0)  55.5 (23.4)    
4-7 73 (29.9) 69.3 (31.9)  68.9 (29.1)    
>8 47 (19.3) 45.2 (20.8)  50.0 (20.6)    
Postpartum visit‡    .16 .02 
Yes 59 (24.2) 53.7 (24.7) 59.3 (25.0)    
No 185 (75.8) 163.3 (75.3)  177.8 (75.0)    
Parity§,||    .18 .02 
>2      
Live birth¶ 96  (39.3) 85.5 (39.4) 93.0 (39.2)   
Non-live birth¶ 28  (11.5) 23.5 (10.8) 27.0 (11.4)   
<2 120 (49.2) 108.0 (49.8)  117.2 (49.4)    
Past contraceptive use§    .02 .005 
Most effective reversible methods 11 (4.51) 10.7 (4.93)  11.2 (4.70)   
Moderately effective method 51(20.9) 43.7 (20.1)  49.3 (20.8)    
No method 182 (74.6) 162.6 (74.9)  176.7 (74.5)    
Medical       
Mental health comorbidities 161 (66.0) 140.3 (64.7) 153.7 (64.8) 1.04 .03 
Chronic conditions#    .23 .06 
0 210  (86.1) 184.3 (84.9) 207.9 (87.7)   
1 29  (11.9) 29.5 (13.6) 26.1 (11.0)   
>2 5  (2.05) 3.21 (1.48) 3.15 (1.33)   
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|| Women with >1 pregnancies in the data were classified as having >2 pregnancies. 
¶ Outcome of the previous pregnancy for women with >1 pregnancies in the 5 years prior to delivery. 
# Includes breast cancer, malabsorptive bariatric surgery, venous thromboembolism, valvular heart disease, systematic lupus erythematosus, liver cancer, 
severe liver cirrhosis, ischemic heart disease, chronic hypertension, stroke, migraine with aura, diabetes with and without complications, peripartum 
cardiomyopathy, malignant gestational trophoblastic disease, epilepsy, ovarian cancer, endometrial cancer, thrombogenic mutations, tuberculosis, sickle 
cell disease, schistosomiasis with fibrosis of liver, and solid organ transplantation. 
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Table 3.2. Postpartum use of most or moderately effective contraceptive methods or no method among South-Carolina 
Medicaid enrolled women aged 15-44 years with and without an opioid use disorder, before and after propensity score 
weighting, 2005-2017 (n=23,326) 
 
OUD, opioid use disorder;  Non-opioid SUD, non-opioid substance use disorder; SUD, substance use disorder. 
Percentages may not add to 100% due to rounding. 
* P values are two-tailed with <.05 indicating statistical significance. 
† P values obtained using the Rao-Scott chi-square statistic to account for propensity score weighted data. 
‡ Most effective contraceptive methods include female sterilization, implants, and intrauterine devices or systems. 
§ Moderately effective contraceptive methods include injectables, oral pills, patch, ring, and diaphragm. 
||Includes methods, such as condoms, sponge, spermicide, withdrawal, or natural family planning, not covered under the Medicaid program. 

























Outcomes n (%) n (%) P n (%) P  n (%) n (%) P n (%) P 
Immediate 
postpartum    .06  <.001 
 
  .91  .84 
Most‡   54 (22.1) 222 (16.1)  2,587 (11.9)   54 (22.1) 50.9 (22.9)  50.2 (21.1)  
Moderate§ 14 (5.74) 76 (5.52)  1,558 (7.18)   14 (5.74) 11.2 (5.03)  12.2 (5.13)  
No method|| 176 (72.1) 1,080 (78.4)  17,559 (80.9)   176 (72.1) 160.2 (72.1)  175.9 (73.8)  
3 months 
postpartum    .11  <.001    .40  .002 
Most‡   75 (30.7) 369 (26.8)  5,151 (23.7)   75 (30.7) 73.2 (35.5)  74.5 (34.7)  
Moderate§ 51 (20.9) 373 (27.1)  7,489 (34.5)   51 (20.9) 42.7 (20.7)  62.0 (28.9)  
No method|| 118 (48.4) 636 (46.2)  9,064 (41.8)   118 (48.4) 90.4 (43.8)  78.2 (36.4)  
6 months 
postpartum    .14  <.001    .56  .02 
Most‡  82 (33.6) 401 (29.1)  5,705 (26.3)   82 (33.6) 78.1 (37.7)  79.4 (37.2)  
Moderate§ 61 (25.0) 427 (31.0)  8,426 (38.8)   61 (25.0) 49.0 (23.6)  65.9 (30.9)  
No method|| 101 (41.4) 550 (39.9)  7,573 (34.9)   101 (41.4) 80.0 (38.6)  68.0 (31.9)  
12 months 
postpartum    .10  <.001     .40  .01 
Most‡   86 (35.3) 432 (31.4)  6,291 (29.0)   86 (35.3) 81.3 (40.3)  79.3 (40.4)  
Moderate§ 68 (27.9) 482 (35.0)  9,136 (42.1)   68 (27.9) 53.3 (26.5)  64.5 (32.9)  
No method|| 90 (36.9) 464 (33.7)  6,277 (28.9)   90 (36.9) 67.0 (33.2)  52.5 (26.8)  
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Table 3.3. Results from multivariable and propensity score weighted logistic regression models examining postpartum 
contraceptive initiation among South Carolina Medicaid-enrolled women without an opioid use disorder compared to women 


















OR, odds ratio; CI, confidence intervals OUD, opioid use disorder; Non-opioid SUD, non-opioid substance use disorder; SUD, substance use disorder. 
* Multivariable models adjusted for age, race-ethnicity, marital status, county of residence, plan type at delivery, year of delivery, number of prenatal 
visits, postpartum visit attendance and outpatient health care utilization in the postpartum period (excluding immediate postpartum), parity, past 
contraceptive use, mental health comorbidities, and chronic conditions.  
† Most effective contraceptive methods include female sterilization, implants, and intrauterine devices or systems. 
‡ Moderately effective contraceptive methods include injectables, oral pills, patch, ring, and diaphragm. 
§ Includes methods, such as condoms, sponge, spermicide, withdrawal, or natural family planning, not covered under the Medicaid program. 
  
 Multivariable models*  Weighted regression models 
 
Most† or moderate‡ 
 vs no method§ 
Most† vs moderate‡ 
 or no method§  
Most† or moderate‡  
vs no method§ 
Most† vs moderate‡  
or no method§ 
 OR (95% CI) OR (95% CI)  OR (95% CI) OR (95% CI) 
Immediate postpartum      
Non-opioid SUD vs OUD 0.94 (0.68-1.30) 1.17 (0.82-1.68)  1.00 (0.71-1.43) 1.05 (0.71-1.53) 
No SUD vs OUD 0.86 (0.64-1.16) 0.89 (0.64-1.25)  0.92 (0.68-1.24) 0.94 (0.68-1.30) 
3 months postpartum      
Non-opioid SUD vs OUD 1.34 (1.01-1.78) 1.33 (0.97-1.83)  1.20 (0.87-1.65) 1.24 (0.89-1.73) 
No SUD vs OUD 1.71 (1.31-2.24) 1.23 (0.99-1.78)  1.63 (1.24-2.15) 1.20 (0.89-1.61) 
6 months postpartum      
Non-opioid SUD vs OUD 1.29 (0.97-1.73) 1.30 (0.95-1.77)  1.12 (0.81-1.55) 1.20 (0.86-1.67) 
No SUD vs OUD 1.72 (1.31-2.25) 1.31 (0.98-1.75)  1.51 (1.12-2.03) 1.17 (0.87-1.58) 
12 months postpartum      
Non-opioid SUD vs OUD 1.37 (1.02-1.84) 1.29 (0.95-1.75)  1.18 (0.84-1.64) 1.24 (0.90-1.73) 
No SUD vs OUD 1.84 (1.40-2.43) 1.34 (1.01-1.78)  1.60 (1.20-2.14) 1.25 (0.94-1.66) 
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Figure 3.2. Predicted probabilities of initiating most or moderately effective contraceptive methods within the immediate 
postpartum period and by 3, 6, and 12 months postpartum for women with non-opioid substance use disorders, women without 
substance use disorders, and women with opioid use disorders. Compared to women with opioid use disorder, there were 
significant differences in predicted probabilities for women without substance use disorders by 3, 6, and 12 months postpartum 
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Figure 3.3. Predicted probabilities of initiating most effective contraceptive methods within the immediate postpartum and by 
3, 6, and 12 months postpartum for women with non-opioid substance use disorders, women without substance use disorders, 
and women with opioid use disorders. Compared to women with opioid use disorders, there were no significant differences in 
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Table S3.1. Demographic, pregnancy and reproductive health, and medical covariates of South Carolina Medicaid-enrolled 




B.  Non-opioid SUD 
(n=1,378) A vs B 
C. No SUD 
(n=21,704) A vs C 
Covariates n (%) n (%) Ph n (%) Ph 
Demographic       
Age group (years)   <.001  <.05 
15-19 35 (14.3) 511 (37.1)  8,229 (37.9)  
20-24 50 (20.5) 335 (24.3)  5,627 (25.9)  
25-34 139 (57.0) 448 (32.5)  6,836 (31.5)  
35-44 20 (8.20) 84 (6.10)  1,012 (4.66)  
Race   <.001  <.001 
Non-Hispanic white 198 (82.5) 711 (52.2)  7,238 (33.6)  
Non-Hispanic black 26 (10.8) 531 (39.0)  13,216 (61.4)  
Hispanic/Latino 2 (0.83) 15 (1.10)  296 (1.38)  
Other race-ethnicity* 14 (5.83) 104 (7.64)  769 (3.57)  
Marital status   .70  .29 
Single 145 (59.4) 768 (55.7)  13,028 (60.3)  
Married 10  (4.10) 62 (4.50)  1,173 (5.40)  
Not married or separated 5  (2.05) 21 (1.52)  189 (0.87)  
Unknown 18 (7.38) 96 (6.97)  1,378 (6.35)  
Missing 66 (27.1) 431 (31.3)  5,936 (27.4)  
County of residence†   .06  .63 
Rural 69 (29.2) 318 (23.6)  5,948 (27.8)  
Urban 167 (70.8) 1032 (76.4)  15,428 (72.1)  
Pregnancy and reproductive health      
Plan type   .001  <.001 
Medicaid managed care 167 (68.4) 793 (57.6)  11,228 (51.7)  
Fee-for-service 77 (31.6) 585 (42.5)  10,476 (48.3)  
Year of delivery   .0003  <.001 
2005 17 (6.97) 164 (11.9)  3,001 (13.8)  
2006 5  (2.05) 161 (11.7)  3,040 (14.0)  
2007 20 (8.20) 108 (7.84)  2,283 (10.5)  
2008 17 (6.97) 67 (4.86)  1,506 (6.94)  
2009 14 (5.74) 64 (4.64)  1,146 (5.28)  


































OUD, opioid use disorder;  Non-opioid SUD, non-opioid substance use disorder; SUD, substance use disorder. 
Percentages may not add to 100% due to rounding. 
* Includes Asian, Native American, and more than one race-ethnicity. 
† Derived using the United States Department of Agriculture’s Urban Influence Codes. 
‡ Within 3 months following delivery. 
2011 11 (4.51) 68 (4.93)  991 (4.57)  
2012 14 (5.74) 73 (5.30)  1,005 (4.63)  
2013 16 (6.56) 85 (6.17)  1,258 (5.80)  
2014 22 (9.02) 118 (8.56)  1,511 (6.96)  
2015 38 (15.6) 161 (11.7)  1,950 (8.98)  
2016 43 (17.6) 158 (11.5)  2,083 (9.60)  
2017 18 (7.38) 80 (5.81)  937 (4.32)  
Number of prenatal visits   .33  .27 
0-1 62 (25.4) 374 (27.1)  5,822 (26.8)  
2-3 62 (25.4) 279 (20.3)  4,507 (20.8)  
4-7 73 (29.9) 429 (31.1)  6,449 (29.7)  
>8 47 (19.3) 296 (21.5)  4,926 (22.7)  
Postpartum visit‡   .20  .02 
Yes 59 (24.2) 388 (28.2)  6,731 (31.0)  
No 185 (75.8) 990 (71.8)  14,973 (69.0)  
Parity§,||   .03  .003 
>2      
Live birth¶ 96  (39.3) 423 (30.7)  6,513 (30.0)  
Non-live birth¶ 28  (11.5) 171 (12.41)  2,206 (10.2)  
<2 120 (49.2) 784 (56.9)  12,985 (59.8)  
Past contraceptive use§   .69  .94 
Most effective reversible 
methods 11 (4.51) 79 (5.73)  915 (4.22)  
Moderately effective methods 51(20.9) 270 (19.6)  4,709 (21.7)  
No method 182 (74.6) 1,029 (74.7)  16,080 (74.1)  
Medical       
Mental health comorbidities 161 (66.0) 636 (46.2) <.001 3,585 (16.5) <.001 
Chronic conditions#   .08  <.001 
0 210  (86.1) 1,248 (90.6)  20,417 (94.1)  
1 29  (11.9) 116 (8.42)  1,220 (5.62)  
>2 5  (2.05) 14 (1.02)  67 (0.31)  
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§ Based on claims in the 5 years prior to delivery. 
|| Women with >1 pregnancies in the data were classified as having >2 pregnancies. 
¶ Outcome of the previous pregnancy for women with >1 pregnancies in the 5 years prior to delivery. 
# Includes breast cancer, malabsorptive bariatric surgery, venous thromboembolism, valvular heart disease, systematic lupus erythematosus, liver cancer, 
severe liver cirrhosis, ischemic heart disease, chronic hypertension, stroke, migraine with aura, diabetes with and without complications, peripartum 
cardiomyopathy, malignant gestational trophoblastic disease, epilepsy, ovarian cancer, endometrial cancer, thrombogenic mutations, tuberculosis, sickle 

















Table S3.2. Postpartum contraceptive use prevalence of most and moderately effective methods among South-Carolina 
Medicaid enrolled women aged 15-44 years with and without an opioid use disorder, before propensity score weighting, 2005-
2017 (n=23,326) 
 Unweighted sample 
 A. OUD 
(n=244) 
B.  Non-opioid SUD 
(n=1,378) A vs B* 
C. No SUD 
(n=21,704) A vs C* 
Outcomes n (%) n (%) P n (%) P 
Immediate postpartum    .14  <.001 
Female sterilization 48 (19.7) 185 (13.4)  2,293 (10.6)  
Intrauterine devices or systems  0 (0.00) 7 (0.51)  65 (0.30)  
Implants 6 (2.46) 30 (2.18)  229 (1.06)  
Injectables 2 (0.82) 5 (0.36)  99 (0.46)  
Oral pills 9 (3.69) 61 (4.43)  1,227 (5.65)  
Patch 3 (1.23) 8 (0.58)  196 (0.90)  
Ring 0 (0.00) 2 (0.15)  36 (0.17)  
Diaphragm 0 (0.00) 0 (0.00)  0 (0.00)  
3 months postpartum   .08  <.001 
Female sterilization 55 (23.0) 246 (17.9)  2,919 (13.5)  
Intrauterine devices or systems  6 (2.46) 63 (4.57)  1,270 (5.85)  
Implants 13 (5.33) 60 (4.35)  962 (4.43)  
Injectables 10 (4.10) 114 (8.27)  1,613 (7.43)  
Oral pills 36 (14.8) 203 (14.7)  4,681 (21.6)  
Patch 2 (0.82) 29 (2.10)  744 (3.43)  
Ring 3 (1.23) 27 (1.96)  448 (2.06)  
Diaphragm 0 (0.00) 0 (0.00)  3 (0.01)  
6 months postpartum   .08  <.001 
Female sterilization 60 (24.6) 255 (18.5)  3,069 (14.1)  
Intrauterine devices or systems  8 (3.28) 77 (5.59)  1,543 (7.11)  
Implants 14 (5.74) 69 (5.01)  1,093 (5.04)  
Injectables 13 (5.33) 133 (9.65)  1,948 (8.98)  
Oral pills 41 (16.8) 238 (17.3)  5,214 (24.0)  
Patch 2 (0.82) 31 (2.25)  764 (3.52)  
Ring 5 (2.05) 25 (1.81)  494 (2.28)  
Diaphragm 0 (0.00) 0 (0.00)  6 (0.03)  
12 months postpartum   .05  <.001 










OUD, opioid use disorder;  Non-opioid SUD, non-opioid substance use disorder; SUD, substance use disorder. 
Percentages may not add to 100% due to rounding. 
* P values are two-tailed with <.05 indicating statistical significance. 
  
Intrauterine devices or systems  8 (3.28) 89 (6.46)  1,801 (8.30)  
Implants 17 (6.97) 79 (5.73)  1,239 (5.71)  
Injectables 17 (6.97) 152 (11.0)  2,166 (9.98)  
Oral pills 43 (17.6) 276 (20.0)  5,736 (26.4)  
Patch 2 (0.82) 27 (1.96)  717 (3.30)  
Ring 6 (2.46) 27 (1.96)  511 (2.35)  
Diaphragm 0 (0.00) 0 (0.00)  6 (0.03)  
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Table S3.3. Results from analyses using alternate sample selection criteria to examine postpartum contraceptive initiation 
among South Carolina Medicaid-enrolled women without an opioid use disorder compared to women with an opioid use 


















OR, odds ratio; CI, confidence intervals OUD, opioid use disorder; Non-opioid SUD, non-opioid substance use disorder; SUD, substance use disorder. 
Notes: Sample included women with continuous enrollment from 36 months before delivery to 12 months postpartum. 
* Multivariable models adjusted for age, race-ethnicity, marital status, county of residence, plan type at delivery, year of delivery, number of prenatal 
visits, postpartum visit attendance and outpatient health care utilization in the postpartum period (excluding immediate postpartum), parity, past 
contraceptive use, mental health comorbidities, and chronic conditions.  
† Most effective contraceptive methods include female sterilization, implants, and intrauterine devices or systems. 
‡ Moderately effective contraceptive methods include injectables, oral pills, patch, ring, and diaphragm. 
§ Includes methods, such as condoms, sponge, spermicide, withdrawal, or natural family planning, not covered under the Medicaid program. 
  
 Multivariable models*  Weighted regression models 
 
Most† or moderate‡ 
 vs no method§ 
Most† vs moderate‡ 
 or no method§  
Most† or moderate‡ 
 vs no method§ 
Most† vs moderate‡ 
 or no method§ 
 OR (95% CI) OR (95% CI)  OR (95% CI) OR (95% CI) 
Immediate postpartum      
Non-opioid SUD vs OUD 0.98 (0.76-1.24) 1.06 (0.82-1.38)  1.03 (0.79-1.31) 1.01 (0.78-1.33) 
No SUD vs OUD 0.89 (0.71-1.10) 0.88 (0.69-1.11)  0.94 (0.76-1.17) 0.93 (0.73-1.17) 
3 months postpartum      
Non-opioid SUD vs OUD 1.22 (1.00-1.50) 1.22 (0.98-1.52)  1.20 (0.96-1.50) 1.16 (0.92-1.47) 
No SUD vs OUD 1.47 (1.21-1.77) 1.16 (0.95-1.43)  1.37 (1.12-1.67) 1.08 (0.88-1.33) 
6 months postpartum      
Non-opioid SUD vs OUD 1.12 (0.91-1.38) 1.22 (0.98-1.51)  1.06 (0.84-1.33) 1.14 (0.90-1.44) 
No SUD vs OUD 1.42 (1.18-1.72) 1.21 (0.99-1.48)  1.30 (1.05-1.60) 1.15 (0.93-1.43) 
12 months postpartum      
Non-opioid SUD vs OUD 1.19 (0.96-1.47) 1.26 (1.01-1.56)  1.16 (0.91-1.47) 1.25 (0.99-1.57) 
No SUD vs OUD 1.48 (1.22-1.81) 1.23 (1.01-1.51)  1.39 (1.12-1.72) 1.18 (0.95-1.45) 
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Table S3.4. Results from complete case analysis examining postpartum contraceptive initiation among South Carolina 



















OR, odds ratio; CI, confidence intervals OUD, opioid use disorder; Non-opioid SUD, non-opioid substance use disorder; SUD, substance use disorder. 
* Multivariable models adjusted for age, race-ethnicity, marital status, county of residence, plan type at delivery, year of delivery, number of prenatal 
visits, postpartum visit attendance and outpatient health care utilization in the postpartum period (excluding immediate postpartum), parity, past 
contraceptive use, mental health comorbidities, and chronic conditions.  
† Most effective contraceptive methods include female sterilization, implants, and intrauterine devices or systems. 
‡ Moderately effective contraceptive methods include injectables, oral pills, patch, ring, and diaphragm. 
§ Includes methods, such as condoms, sponge, spermicide, withdrawal, or natural family planning, not covered under the Medicaid program. 
 
  
 Multivariable models*  Weighted regression models 
 
Most† or moderate‡ 
 vs no method§ 
Most† vs moderate‡ 
 or no method§  
Most† or moderate‡ 
 vs no method§ 
Most† vs moderate‡ 
 or no method§ 
 OR (95% CI) OR (95% CI)  OR (95% CI) OR (95% CI) 
Immediate postpartum      
Non-opioid SUD vs OUD 1.08 (0.74-1.58) 1.40 (0.92-2.15)  1.02 (0.72-1.45) 1.08 (0.74-1.58) 
No SUD vs OUD 0.98 (0.69-1.39) 1.03 (0.69-1.53)  0.92 (0.68-1.24) 0.94 (0.68-1.32) 
3 months postpartum      
Non-opioid SUD vs OUD 1.49 (1.07-2.07) 1.37 (0.95-1.97)  1.19 (0.86-1.64) 1.22 (0.87-1.73) 
No SUD vs OUD 1.82 (1.34-2.48) 1.27 (0.90-1.78)  1.69 (1.29-2.21) 1.17 (0.88-1.57) 
6 months postpartum      
Non-opioid SUD vs OUD 1.40 (1.00-1.95) 1.34 (0.94-1.91)  1.08 (0.78-1.51) 1.16 (0.83-1.63) 
No SUD vs OUD 1.81 (1.33-2.47) 1.23 (0.88-1.71)  1.64 (1.25-2.16) 1.18 (0.89-1.57) 
12 months postpartum      
Non-opioid SUD vs OUD 1.45 (1.03-2.04) 1.37 (0.96-1.95)  1.15 (0.82-1.62) 1.20 (0.86-1.67) 
No SUD vs OUD 1.93 (1.40-2.64) 1.34 (0.97-1.87)  1.66 (1.25-2.20) 1.23 (0.93-1.62) 
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Table S3.5. Results from sensitivity analyses using a restricted exposure definition to examine postpartum contraceptive 
initiation among South Carolina Medicaid-enrolled women without an opioid use disorder compared to women with an opioid 


















OR, odds ratio; CI, confidence intervals OUD, opioid use disorder;  Non-opioid SUD, non-opioid substance use disorder; SUD, substance use disorder. 
Notes: Exposure variable was ascertained by identifying specific diagnosis codes, procedure codes, and National Drug Code numbers (listed in 
Appendix A) on medical and pharmacy claims in the 2 years prior to delivery. OUD: n= 129;  Non-opioid SUD: n=838; No SUD: n=22,359. 
* Multivariable models adjusted for age, race-ethnicity, marital status, county of residence, plan type at delivery, year of delivery, number of prenatal 
visits, postpartum visit attendance and outpatient health care utilization in the postpartum period (excluding immediate postpartum), parity, past 
contraceptive use, mental health comorbidities, and chronic conditions.  
† Most effective contraceptive methods include female sterilization, implants, and intrauterine devices or systems. 
‡ Moderately effective contraceptive methods include injectables, oral pills, patch, ring, and diaphragm. 
§ Includes methods, such as condoms, sponge, spermicide, withdrawal, or natural family planning, not covered under the Medicaid program. 
  
 Multivariable models*  Weighted regression models 
 
Most† or moderate‡ 
 vs no method§ 
Most† vs moderate‡ 
 or no method§  
Most† or moderate‡ 
 vs no method§ 
Most† vs moderate‡ 
 or no method§ 
 OR (95% CI) OR (95% CI)  OR (95% CI) OR (95% CI) 
Immediate postpartum      
Non-opioid SUD vs OUD 0.88 (0.58-1.36) 1.12 (0.69-1.81)  1.20 (0.74-1.95) 1.37 (0.81-2.31) 
No SUD vs OUD 0.86 (0.57-1.27) 0.94 (0.60-1.47)  0.93 (0.62-1.40) 0.98 (0.63-1.53) 
3 months postpartum      
Non-opioid SUD vs OUD 1.44 (0.98-2.12) 1.65 (1.06-2.56)  1.56 (1.02-2.37) 1.63 (1.03-2.59) 
No SUD vs OUD 1.84 (1.28-2.63) 1.65 (1.10-2.50)  1.78 (1.22-2.56) 1.57 (1.04-2.37) 
6 months postpartum      
Non-opioid SUD vs OUD 1.22 (0.83-1.80) 1.46 (0.96-2.23)  1.40 (0.90-2.18) 1.48 (0.93-2.36) 
No SUD vs OUD 1.64 (1.14-2.37) 1.52 (1.02-2.26)  1.54 (1.06-2.25) 1.45 (0.98-2.16) 
12 months postpartum      
Non-opioid SUD vs OUD 1.50 (1.01-2.23) 1.54 (1.01-2.34)  1.89 (1.21-2.95) 1.77 (1.11-2.81) 
No SUD vs OUD 2.00 (1.38-2.89) 1.63 (1.10-2.41)  1.73 (1.18-2.55) 1.43 (0.96-2.11) 
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Table S3.6. Results from subgroup analyses examining postpartum contraceptive initiation among South Carolina Medicaid-



















OR, odds ratio; CI, confidence intervals OUD, opioid use disorder;  Non-opioid SUD, non-opioid substance use disorder; SUD, substance use disorder; 
NA, not applicable. 
Notes: Propensity score and outcome models included polysubstance use (yes vs no) in the model specification. 
* Multivariable models adjusted for age, race-ethnicity, marital status, county of residence, plan type at delivery, year of delivery, number of prenatal 
visits, postpartum visit attendance and outpatient health care utilization in the postpartum period (excluding immediate postpartum), parity, past 
contraceptive use, mental health comorbidities, chronic conditions, and polysubstance use.  
† Most effective contraceptive methods include female sterilization, implants, and intrauterine devices or systems. 
‡ Moderately effective contraceptive methods include injectables, oral pills, patch, ring, and diaphragm. 
§ Includes methods, such as condoms, sponge, spermicide, withdrawal, or natural family planning, not covered under the Medicaid program. 
 
 Multivariable models*  Weighted regression models 
 
Most† or moderate‡ 
 vs no method§ 
Most† vs moderate‡ 
 or no method§  
Most† or moderate‡ 
 vs no method§ 
Most† vs moderate‡ 
 or no method§ 
 OR (95% CI) OR (95% CI)  OR (95% CI) OR (95% CI) 
Immediate postpartum      
Non-opioid SUD vs OUD 1.09 (0.77-1.55) 1.20 (0.82-1.77)  1.07 (0.74-1.56) 1.11 (0.75-1.66) 
No SUD vs OUD NA NA  NA NA 
3 months postpartum      
Non-opioid SUD vs OUD 1.33 (0.98-1.83) 1.43 (1.01-2.02)  1.25 (0.91-1.72) 1.26 (0.90-1.77) 
No SUD vs OUD NA NA  NA NA 
6 months postpartum      
Non-opioid SUD vs OUD 1.28 (0.93-1.76) 1.41 (1.00-1.99)  1.20 (0.86-1.66) 1.27 (0.90-1.79) 
No SUD vs OUD NA NA  NA NA 
12 months postpartum      
Non-opioid SUD vs OUD 1.40 (1.01-1.95) 1.44 (1.03-2.03)  1.23 (0.88-1.72) 1.29 (0.93-1.79) 




 “WE’RE NOT THE CAPTAIN OF THE SHIP, THE PATIENT IS”: 
HEALTH CARE PROVIDERS’ CONTRACEPTIVE COUNSELING PRACTICES 





Objective: Women with substance use disorders (SUD) have high rates of unintended 
pregnancy, yet little research exists on how health care providers perform contraceptive 
counseling for their patients with SUD. This study explored health care providers’ self-
reported contraceptive counseling practices for women with SUD. 
Study Design: We conducted semi-structured qualitative interviews with a national, 
purposive sample of medical doctors (n=10) and advanced practice nurses (n=14) in four 
US Census Bureau-designated regions. Interviews were audio-recorded and transcribed 
verbatim. A two-member team conducted thematic analysis in Atlas.to v8 using top-
down (deductive) and bottom-up (inductive) codes to construct themes. 
Results: Five major themes were identified. Providers reported timing contraceptive 
discussions and tailoring information uniquely for their patients with SUD. They also 
emphasized the importance of building interpersonal relationships and prioritizing 
patients’ autonomy while counseling patients with SUD. Many providers perceived that 
long-acting reversible contraceptives were more appropriate than short-acting reversible 
contraceptive methods for women with SUD who may experience social instability in 
their lives. 
Conclusion: Providers reported several considerations for optimizing contraceptive 
counseling for women with SUD. They emphasized the importance of providing 





Despite modern innovations in family planning technologies and service delivery, 
many women with substance use disorders (SUD) in the United States (US) are not 
accessing contraception. Women with SUD have lower overall rates of contraceptive use 
[1–3] and a higher reliance on less effective methods [1,3,4] than women without SUD. 
Though robust evidence is still lacking, they may also have poorer contraceptive 
adherence patterns [3,5], which could partly explain high rates of unintended pregnancy 
in this population. Across US studies, unintended pregnancy rates among women with 
SUD typically exceed 75% [4,6,7], compared to approximately 45% in the general 
population [8].  
Integrating reproductive health services into SUD treatment locations has been 
proposed as one solution to meet the contraceptive needs of women with SUD. While 
research has shown the feasibility [9,10] and acceptability [9,11,12] of this strategy, 
studies investigating integrated reproductive health/SUD treatment services have reported 
mixed results on contraceptive use outcomes. In a recent study among pregnant women 
with opioid use disorder (OUD), those who received integrated medication assisted 
treatment (MAT) and women’s services, including family planning, were more likely to 
use long-acting reversible contraceptives (LARC) within six weeks of delivery than 
women in traditional MAT [13]. However, a more recent study among pregnant women 
with OUD reported that co-location of prenatal care with MAT was not associated with 
increased postpartum contraceptive uptake by the postpartum visit [14]. To our 
knowledge, no similar studies among non-pregnant women have been conducted. 
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Contraceptive counseling is another strategy to improve contraceptive outcomes 
for women with SUD. Contraceptive counseling can help women overcome information-
related barriers to accessing family planning, especially LARC, by providing them with 
accurate information and education about the safety and efficacy of various methods. 
Several studies have reported that women with SUD who are interested in using LARC 
would benefit from generalized education about LARC methods and specific 
communications related to their safety, efficacy, and side effects [4,15]. In studies 
conducted among general populations, contraceptive counseling in clinical settings is 
associated with increased contraceptive knowledge as well as improved contraceptive use 
outcomes, including initiation, continuation, and correct use [16]. Research has also 
demonstrated that contraceptive counseling impacts decision-making about method 
choice [17] and that higher quality patient-provider communication is associated with 
continuation of a chosen method [18].  
The American College of Obstetricians and Gynecologists (ACOG) recommends 
contraceptive counseling as a routine part of SUD treatment [19]. Yet, contraceptive 
counseling approaches for women with SUD remains a largely unexplored area of 
research. This study investigated health care providers’ self-reported contraceptive 
counseling practices for women with SUD in varying stages of addiction recovery. Our 
primary goal was to explore patient-provider communication within the context of 
contraceptive provision. 
2. MATERIALS AND METHODS  
 
2.1 Sample and Recruitment 
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After receiving approval from the Clemson University Institutional Review 
Board, a purposive sample of women’s health providers was recruited from across the 
US. In this study, providers were defined as health care practitioners with prescriptive 
authority. Providers were eligible for participation in the study if they actively perform 
contraceptive counseling for women with SUD. Providers that practiced in correctional 
institutions were excluded (n=1) due to state-level differences in contraceptive services 
delivery within correctional settings. To enhance sampling variation, we recruited 
participants to represent a wide variety of health care specialties and geographic locations 
in the US. The desired sample size for maximum variation was at least two medical 
doctors (MD) and two advanced practice nurses (APN) from each of the US Census 
Bureau’s four designated regions (i.e. Midwest, Northeast, Southeast, and West). 
To recruit study participants, we contacted national and state professional 
associations and consortiums of women’s health providers to request assistance in 
reaching out to their members. Potential participants were introduced to the study through 
a mix of direct email contact, social media, and digital newsletters and invited to schedule 
a phone interview. Interested parties contacted a project team member by email or text 
message or completed a Google Form to enroll. After eligibility was determined, 
participants were emailed an informational letter about the study. No incentives were 
offered for research participation. Recruitment continued until the target sample size was 
reached. 
2.2 Data Collection 
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One project team member (E.C.) conducted semi-structured interviews lasting 
approximately 30 minutes between February 2019 and May 2019. A moderator guide 
was developed and pilot tested with two APN before starting data collection. After 
revising items for clarity and length, the final guide consisted of six open-ended questions 
that broadly queried providers about contraceptive counseling provision for women with 
SUD. Providers were queried about multiple facets of counseling, including the context 
in which counseling takes place, information shared at visits, and communication 
approaches. We used probing questions to explore differences in the provision of 
counseling for women in their active addiction as compared to those in recovery, as well 
as for women without SUD. With participants’ consent, interviews were digitally 
recorded and then transcribed verbatim by a professional transcription service. For 
quality assurance, transcribed interviews were compared to original recordings and 
corrected as needed. 
2.3 Data Analysis 
 
Data were analyzed using a thematic analysis approach, which is a commonly 
used analysis technique for identifying and reporting patterns of meaning in data [20]. 
Using Braun and Clarke’s six phases to thematic analysis to guide the process, two 
members of the study team (E.C. and S.H-S.) independently coded the transcripts by 
applying empirical codes (inductive) and pre-existing codes based on the moderator 
guide and a review of the literature (deductive). The team met during the coding process 
to address consensus, develop new codes, and update the coding structure. After code 
saturation was reached at 10 interviews, team members recoded all 24 transcripts using 
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the final codebook. Codes were then collated and overall themes constructed, which were 
discussed with the other authors who provided feedback on the interpretation of the 
findings. ATLAS.ti 8 software [21] was used for all steps of the analysis. 
3. RESULTS 
Characteristics of the sample are displayed in Table 4.1. A total of 24 providers, 
including 10 medical doctors and 14 APN, participated in the study. Participants were 
nearly evenly distributed between the four US Census Bureau-designated regions, with 
most providers residing in the Midwest (29.2%) and the fewest providers residing in the 
Northeast (20.8%). A majority of providers were female (91.7%) and aged 35-44 years 
(45.8%). More than three quarters of participants had been providing contraceptive care 
to women with SUD for five or less years (41.7%) or between six and 15 years (37.5%). 
Five major themes were constructed from deductive and inductive coding 
processes: 1) timing contraceptive discussions; 2) tailoring information; 3) building 
interpersonal relationships; 4) prioritizing patient autonomy; and, 5) advising on 
contraceptive methods. Themes are summarized below using illustrative quotes from 
participant interviews. Additional illustrative quotes for each theme are presented in 
Table 4.2. 
3.1 Timing contraceptive discussions 
 
Of several providers who cared for pregnant women, some reported initiating prenatal 
contraceptive counseling in the third trimester and others in the first trimester. Among 
these providers, a majority mentioned discussing contraception at one or two visits only, 
while a few mentioned discussing it at every prenatal care visit. Of providers who treated 
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non-pregnant patients, many reported discussing contraceptives at each patient-provider 
interaction, and others stated that it depends on the reason for the visit. One provider 
explained the decision to not engage in contraceptive discussions with certain patients in 
their active addiction: 
 
“I feel like people come in for one really specific reason, especially if they’re actively 
using. Sometimes they’re just in for, I had this exposure or you know, and they’re less 
interested in kind of overall well-being or counseling about well-being and so, it’s not 
appropriate in that time. They’re not open to it necessarily.” 
Certified Nurse-Midwife, Northeast 
 
Several providers suggested that contraceptive counseling is of lower importance than 
other patient needs. These providers generally described waiting to discuss contraceptives 
until after patients receive treatment for comorbid conditions or achieve stabilization in 
substance abuse treatment. Some providers who serve pregnant women also discussed 
postponing contraceptive counseling until after the first obstetric visit due to the limited 
time that providers have with patients to address more important pregnancy related 
topics. One provider described how medical priorities and time constraints influence 
timing of contraceptive discussions with pregnant patients with SUD: 
 
“If somebody is coming in and… getting their addiction under control, we probably 
are not talking about contraception at that point. They’re pregnant. We’re trying to 
get their addiction taken care of… It’s probably going to be the second, third, fourth 
meeting with them that we then talk about that preventative stuff.  And not because 
it’s not important, it’s just because literally time constraints and what needs to be 
taken care of at that point.” 
Psychiatrist, Southeast 
 
3.2 Tailoring information  
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Most providers described sharing similar contraceptive information with all patients. 
Contraceptive effectiveness, risks/benefits, side effects, contraindications, and safety 
were commonly mentioned as discussion topics. Many providers also revealed sharing 
information about pregnancy within the context of the patients’ SUD. They mentioned 
discussing the risk of pregnancy complications, adverse pregnancy and birth outcomes, 
and longer-term effects of prenatal substance exposure on the child. MAT medications 
and dosing regimens were reported as additional counseling topics for women with OUD. 
One provider described tailoring information based on the type of substance use 
diagnosis: 
 
“With opioid use disorder I’ll talk about things like neonatal abstinence syndrome, 
irritability, and withdrawal and what that could look like. Other people are smoking 
during their pregnancy and talking about complications, especially the 
neurodevelopment of their child with exposure to THC. Same thing with alcohol as 
well, talking about fetal alcohol syndrome… I have some ladies that I’ve had to 
counsel about nicotine as well and things like cleft lip, cleft palate, just discussing 
what exposure to the fetus in utero to these substances, complications that could 
arise.” 
Family Nurse Practitioner, Midwest 
 
Several providers reported individualizing family planning communications for 
patients with SUD. To initiate personalized counseling, providers described asking 
patients open-ended questions about their reproductive goals or experiences with past 
contraceptive use, and for pregnant women, about their pregnancy intentions after 
childbirth. In an effort to help patients make informed decisions about pregnancy 
planning or prevention, some providers also discussed engaging women who were in 
their active addiction or in early recovery to consider how having children would fit into 
their current situation or impact their recovery. 
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3.3 Building interpersonal relationships  
 
Many providers described the importance and complexities of building interpersonal 
relationships with their patients with SUD. These providers discussed the history of 
negative and punitive attitudes from the medical community toward pregnant women 
who use substances. They mentioned that their patients with SUD are often distrustful of 
health care professionals. To develop a good rapport with patients, many providers stated 
that it is essential to present information in a neutral, unbiased manner. One provider 
explained how contraceptive information is most effectively delivered to patients with 
SUD:  
 
“It’s a very nuanced discussion with every woman, but specifically with women in 
recovery because it so easily can be interpreted by them as you saying the only thing 
that’s going to help you in this world is for you not to have another child… It has to 
be presented in such a way that women don’t feel like you are introducing the idea of 
contraception in the setting of saying they shouldn’t be mothers again.”  
Obstetrician-Gynecologist, Northeast 
 
Several providers described how they build interpersonal relationships with their patients 
with SUD. Strategies included establishing a friend-like rapport during patient-provider 
interactions, framing discussions around pregnancy and parenting in the positive rather 
than the negative, and showing genuine care and concern for the mother-baby dyad 
instead of just the baby.  
3.4 Prioritizing patient autonomy   
 
Many providers stressed that their role in family planning is to provide information 
about contraceptive options and not to influence their patients’ reproductive health or 
contraceptive decisions. These providers emphasized that women with SUD, like other 
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women, have the right to make their own reproductive choices and to select contraceptive 
methods that best fit their lifestyles. Some providers expressed that empowering patients 
to take charge of their own reproductive health is an important part of caring for patients 
with SUD. One provider described her perceived role in providing contraceptive 
counseling to patients with SUD: 
 
“I feel like it’s my job to let them know that they are still in charge of their bodies and 
that if they do want a pregnancy or they do want to become a parent, then that is okay 
and we’ll support them through that.” 
Family Medicine Physician, West 
 
A majority of providers discussed the importance of prioritizing patient autonomy 
when providing contraceptive services to women with SUD. Most stated that patient 
autonomy assumes priority over counseling patients on highly effective methods. A few 
of these providers mentioned advising against tubal ligations because of the permanency 
of the procedure. Several providers shared that they must recognize and control their own 
biases about patients’ reproductive health decisions to perform effective counseling for 
women with SUD. One provider said: 
 
“They still get to make their own choice no matter what I say or whatever. There are 
people who, you know, have six or seven kids and they’re coming and they’ve had this 
really complicated social life. They don’t want a tubal where you in your mind, 
you’re going, you need this, you know. Because they’re in control of their life. So you 
have to work with whatever, you know, however they see that going.” 
Women’s Health Nurse Practitioner, Southeast 
 
3.5 Advising on contraceptive methods 
 
Many providers described counseling patients with SUD on the advantages of 
LARC methods, especially women in their active addiction or in early recovery. Several 
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providers discussed that their patients with SUD experience barriers that make it difficult 
for them to comply with short-acting reversible contraceptive (SARC) methods. Common 
barriers included housing instability, transportation or financial issues, reproductive 
coercion by partners, low health care utilization, and poor postpartum follow-up. One 
provider described the decision to counsel patients with SUD about LARC methods: 
 
“I really don’t push it on them, it’s more of a discussion and letting them make the 
decision, but I definitely encourage them to consider the benefits of a LARC method when 
they are telling me and they’re hearing themselves tell me about a significant amount of 
instability in their lives and the inability to control certain aspects of their lives in the 
midst of addiction.”  
Family Medicine Physician, West 
 
Some providers perceived that their patients with SUD who had a longer time in 
treatment and more stable living situations could do well with SARC methods. For 
women with OUD maintained on daily buprenorphine, several providers perceived that 
these patients would have improved adherence to oral contraceptives compared to other 
patients with SUD. One provider explained: 
 
“I think the person who is stable on their Buprenorphine and they’re already taking it 
once per day, they can take their birth control pill at the same time.  That person is 
probably an okay option for using shorter term contraceptives.” 
Certified Nurse-Midwife, Southeast 
 
A few providers also mentioned emphasizing barrier methods for women who were in 
their active addiction. However, most providers discussed the risk of sexually transmitted 




Providers described varying approaches to timing contraceptive discussions with 
their patients with SUD. Primarily they reported postponing family planning care to a 
point after patients achieve stability in medical care or in substance abuse treatment. For 
obstetric providers, postponing family planning conversations was also related to limited 
time and competing demands during antenatal care appointments. Although 
recommendations are that women should receive family planning care at prenatal and 
postpartum visits, there are currently no specific guidelines on how often or during which 
visit antenatal contraceptive counseling should be performed [22]. In one study 
examining contraceptive care preferences of low-income, underserved women, 
researchers found that participants preferred short, frequent contraceptive counseling 
discussions throughout the prenatal period [23]. No studies have examined whether such 
a strategy could improve postpartum contraceptive use outcomes. However, national 
survey data suggest that counseling provided in the prenatal and postpartum periods is 
more effective for promoting contraceptive uptake than when it is provided in either 
period alone [24]. Given the unique treatment needs of women with SUD, it is important 
for future research to examine women’s preferences for the frequency and timing of 
contraceptive discussions, as well as how these factors influence contraceptive uptake, in 
this population. 
Consistent with reproductive life planning approaches outlined by ACOG [25], 
many providers initiated contraceptive discussions with their patients with SUD by 
asking about future reproductive intentions. Providers described asking open-ended 
questions to elicit information about patients’ reproductive health goals and engaging in 
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personalized counseling about contraceptive methods based on their responses. Providers 
also reported tailoring information about pregnancy uniquely for women with SUD and 
empowering patients to make autonomous decisions about their own reproductive health 
and fertility. These self-described practices are consistent with a patient-centered 
approach to contraceptive counseling, which prioritizes individualized counseling to help 
patients make informed choices about the best contraceptive methods for their situations 
over counseling towards methods with the highest efficacy [26,27]. Prior research 
indicates that patient-centered care can improve patient satisfaction and perceived quality 
of care, build trust and understanding between clinicians and patients, and enhance and 
facilitate collaborative decision making [28]. In the context of family planning care, 
studies have found that patient-centeredness is aligned with patients’ preferences for 
patient-provider communication [29,30] and associated with improved contraceptive use 
outcomes [31]. 
Patient-centered contraceptive care may be an especially important consideration 
for women with SUD. There is a long history in the US and elsewhere of practices of 
stigma and discrimination toward persons who use drugs. While current evidence 
recognizes addiction as a chronic, relapsing biologic disorder [32], there still exists a 
widely held public view that people who use drugs are dangerous, unpredictable, and to 
blame for their disease [33]. Society has responded to these narratives by developing and 
implementing policies to criminalize and marginalize people who engage in drug use, a 
burden that falls disproportionately on people of color and people in low socioeconomic 
brackets. The capacity of women who use drugs to be fit mothers has further been called 
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into question because of the potential of maternal substance use to cause fetal harm. 
Pregnant drug users have been subject to legal and social interventions, such as 
compulsory treatment, loss of parental custody, arrest, prosecution, and conviction, in the 
name of protecting the fetus from the risks of prenatal drug exposure [34]. Providers in 
this study were sensitive to the discrimination and stigmatization that women with SUD 
may experience in health care settings and maintained that these practices create barriers 
to seeking care and treatment within this population. To build trusting relationships with 
their patients with SUD, providers discussed the importance of providing non-
judgmental, empathetic care and not pressuring patients to choose the most effective 
contraceptive methods.  
Even so, many providers perceived that LARC methods are the best contraceptive 
options for some patients with SUD, particularly women in their active addiction or in 
early recovery. This was not due to the substance use itself or the high risk of unintended 
pregnancy among women with SUD. Rather, these providers asserted that based on their 
medical experience women with multiple forms of instability in their lives have difficulty 
sustaining user-dependent contraceptives. Past research indicates that women with SUD 
experience unique barriers to contraceptive access and continuation that may not be 
experienced by other women. Such barriers include a perceived low risk of pregnancy 
from substance use [11,35–37], decreased health care utilization during periods of active 
substance use [9,12], drug-induced sexual dysfunction or loss of interest in sex [35,37], 
or desire to become pregnant as a means for achieving sobriety or accessing addiction 
treatment [35,37]. Like other underserved, marginalized populations, women with SUD 
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may also experience significant intra-/inter-personal barriers, including co-occurring 
psychiatric disorders, trauma exposure, and interpersonal violence, and systems-level 
barriers to contraceptive use [9,35,38,39]. Notably, providers in this study believed that 
women with OUD who were maintained on daily buprenorphine were more likely than 
other patients with SUD to be compliant with daily oral contraceptives. Future research 
that examines the relationship between MAT type and SARC adherence and continuation 
among women with OUD may offer clinical guidance for providers who deliver family 
planning care to this population.  
To our knowledge, this is the first study to investigate how health care providers’ 
perform contraceptive counseling for women with SUD in a national sample of diverse 
providers. These findings must be interpreted with several limitations in mind. A small 
number of providers with varying specialties and from different regions of the US were 
recruited into the study. Therefore, we were unable to draw conclusions about differences 
in contraceptive care practices based on provider type or region. Because participants 
self-selected into the interviews, it is likely that providers who responded to recruitment 
advertisements have different perceptions of counseling patients with SUD than those 
who did not respond, or than providers who do not provide contraceptive counseling to 
patients with SUD. The study sample consisted of all Caucasian providers, and responses 
given by these providers may not be generalizable to persons of other racial and ethnic 
groups. Finally, practices described by the providers in our sample were self-reported and 
may not be reflective of their actual contraceptive counseling practices for their patients 




This study examined health care providers’ contraceptive counseling practices for 
women with SUD. While most providers in this study stressed the importance of not 
providing differential counseling for any patient, they also described several important 
considerations for providing contraceptive care to patients with SUD. These included 
timing contraceptive discussions appropriately, tailoring pregnancy-related information, 
providing non-judgmental, compassionate care, and respecting patients’ reproductive 
autonomy. Providers also shared how the medical, treatment, and psychosocial needs of 
their patients shape discussions around contraceptive methods. Though providers in this 
study generally described engaging in patient-centered contraceptive counseling with 
women with SUD, they also reported experiencing negative feelings towards women’s 
reproductive health choices at times. This finding underscores the importance of 
providers recognizing their own perceptions and views related to substance abuse and 
preventing their own biases from influencing contraceptive provision for substance-using 
patients. To understand the best counseling approaches for women with SUD, additional 
research is needed to examine the family planning preferences, needs, and perspectives of 
women in varying stages of addiction or recovery. Understanding when and how women 
with SUD want to receive contraceptive counseling is critical to ensuring the delivery of 
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Abbreviations: SUD, substance use disorder 
*Based on United States Census Bureau-designated regions 
** Column does not add to 100% because providers can contribute to more than one category  
Table 4.1. Characteristics of health care providers in the sample (N=24) 
 n % 
Provider type   
Medical doctor 10 41.7 
Advanced practice nurse 14 58.3 
Provider region*   
Northeast 5 20.8 
Midwest 7 29.2 
South 6 25.0 
West 6 25.0 
Provider’s medical sub-/specialty   
Physician**   
Addiction medicine 6 29.2 
Family medicine 4 16.7 
Obstetrics and gynecology or maternal-fetal 
medicine 5 20.8 
Psychiatry 1 4.20 
Nurse   
Certified nurse-midwife 6 42.9 
Family or adult nurse practitioner 2 14.3 
Women’s health nurse practitioner 5 35.7 
Psychiatric-mental health nurse practitioner 1 7.14 
Age (years)   
25-34 4 16.7 
35-44 11 45.8 
45-54 3 12.5 
55-64 4 16.7 
> 65 2 8.33 
Gender   
Female 22 91.7 
Male 2 8.33 
Race/ethnicity   
Non-Hispanic white 24 100 
Years contraceptive counseling women with SUD   
< 5 10 41.7 
6-15 9 37.5 
> 16 5 20.8 
Average number of patients seen per week   
< 50 6 25.0 
50-80 7 29.2 
81-125 5 20.8 
> 125 6 25.0 
Percentage of patients with a diagnosed SUD   
< 25% 14 58.3 
25-75% 6 25.0 
> 75% 4 16.7 
51 126 
Table 4.2. Themes and additional illustrative quotes 
Theme Illustrative Quotes 
Timing contraceptive discussions 
Waiting  “You know, you want to kind of get them through that withdrawal or whatever they’re going through and get 
stable and then talk to them about it [contraceptives].” 
Women’s Health Nurse Practitioner, Southeast 
 
“People that are just coming in, it’s almost like we’re focused on the here and now of stabilization where it’s, 
hey you are not in a good place right now. We need to get you stabilized. When they’re stabilized, it’s okay, 
what are your fertility goals?.”  
Family Nurse Practitioner, Midwest 
 
Postponing “I think it’s just complete overload with all of the things they’re trying to accomplish every day and plan and 
trying to balance everything and you know the overwhelming concern for social services kind of clouds 





Contextualizing “The counseling around contraception doesn’t change so much as the counseling around what it would look 
like to be pregnant and to be parents.”  
Family Medicine Physician, West 
 
Engaging “If they’re in active addiction… I definitely would warn them without being judgmental that if you think life is 
tough now, just get pregnant…and seriously think about a pregnancy and how much that might compromise 
or complicate your treatment at this time.” 
Obstetrician-Gynecologist, Midwest 
 
“One thing I do ask them is ‘if you were to get pregnant right now, would you continue the pregnancy or 
would you terminate the pregnancy?’ And I think that’s an important piece for them to think through. Because 
if they would never have an abortion, then what I’ll say to them is ‘I want you to not be in the position where 
you have to make that choice.’” 





Building interpersonal relationships 
Complexities  “We have such an important, painful history of coercing women into sterilization who use substances and 
there still persists this kind of cultural and medical community belief that women who use drugs are unfit 
mothers… and so, you know, I wouldn’t want it to be where somehow I was really laying it on heavy for 
women in active use and them getting the impression that I didn’t want them to get pregnant because of their 
substance use.”   
Family Medicine Physician, West 
 
Strategies  “We talk about all kinds of stuff that has absolutely nothing to do with why they’re there. And I think that 
helps a lot. I know about their dogs. I know about their jobs. I know they had this terrible visit with their in-
laws that they hate last week, you know what I mean? Just like personal stuff or some funny story about my 
dogs because they know about my dogs and my kids and stuff too. So, it’s more of a, it’s a visit, but it’s also 
social. So, I think that helps bring them back. It’s rare that my patients don’t come to their appointments.”   
Certified Nurse-Midwife, Midwest 
 
“A lot of women who struggle with substance use disorder have heard in the press or from other people that 
when they’re pregnant what we care about is their baby. I really try to message that my priority is not just 
getting you through this pregnancy, I want to see you healthy for the rest of your life.  My priority is you and 
if I’m doing my job, you have to be healthy. That, I think, helps women feel more comfortable, and yes, I care 
about your baby, but I equally or even more care about what happens to you.”  
Maternal-Fetal Medicine Physician, Midwest 
 
Prioritizing patient autonomy 
Provider role “It is my job as a physician to help people to understand what are the pros and cons, what the risk/benefit is. 
But then they’re still allowed to make the decision of getting pregnant while they’re using or continuing a 
pregnancy despite their substance use or having an abortion because of their substance use.”   
Family Medicine Physician, West 
 
“I just try to really educate them. And really, that’s their decision.  I’m not the one in their shoes. I can have 
an opinion, but it’s not my job to offload my opinion on them.” 




“I know that there are times when I’m like, oh wow, I’d really love for you to be more healthy in terms of your 
substance use before you get pregnant, but I don’t get to choose that for them.”  
Family Medicine Physician, West 
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Advising on contraceptive methods 
LARC “For those who are not far into recovery, I try to talk to them about, you know, the ease of having an IUD in 
that they don’t have to worry about it. I’ll probably say, you know, your life is sort of crazy, are you having 
anymore babies?  Do you want babies?  If you do, that’s fine with me, I don’t care, it doesn’t matter. But, 
you’re out on the street and you’re living under a bridge and it’s very unlikely that you’re going to remember 
to take birth control. So, for her, I probably would be a little bit more encouraging of an IUD…And if they say 
to me no, my preference is for the pill, I’ll say, okay that’s cool, whatever, it’s all about choices.” 
Certified Nurse-Midwife, Midwest 
 




SARC “Women who are on Buprenorphine, I try to talk with them about, okay, if you really only feel comfortable 
with the pill, then combine it with your Suboxone. They’re not going to forget their Suboxone. You know, 
those folks actually could make it work. For folks who are not taking something regularly, I really sort of push 
for the LARC.” 
Obstetrician-Gynecologist, Northeast 
 
“They’re able to take a pill every day, some of the ones that are well-managed, okay they can do that.” 
Certified Nurse-Midwife, West 
 
Barrier “I focus more on the need for barrier contraception and the sexually transmitted infection risk in women who 
are not in recovery.” 









The goal of this dissertation was to examine contraceptive provision and initiation 
trends, patterns, and practices among reproductive-age women with and without SUD. 
Aim 1 examined changes in contraceptive provision from 2000-2017 for South Carolina 
Medicaid-enrolled women with and without SUD aged 15-44 at risk of unintended 
pregnancy. Aim 2 compared postpartum contraceptive initiation patterns in South 
Carolina Medicaid-enrolled women with and without OUD aged 15-44. Aim 3 
investigated health care providers’ contraceptive counseling practices for reproductive-
age women with SUD in varying stages of addiction recovery. The studies presented in 
this dissertation collectively add to our understanding of how women with SUD are 
provided with and use contraception during their childbearing years and may be useful to 
inform public health and clinical interventions to improve access to and quality of 
contraceptive services for women with SUD. Here we summarize the findings from each 
chapter and conclude by discussing the clinical and public health implications of this 
work and future research directions.  
Overview of dissertation findings 
Trends in contraceptive provision 
Chapter 2 described changes in contraceptive provision from 2000-2017 for 
reproductive-age women with and without SUD enrolled in SC Medicaid. This study 
applied NQF-endorsed clinical performance measures for contraceptive care to calculate 
annual unadjusted rates of MME and LARC provision for women with and with SUD. 
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Percentages were stratified by patient characteristics to identify subgroups of women 
with particularly low access (i.e. LARC provision less than 2%) to contraceptives during 
the study period.  
The percentage of SC Medicaid-enrolled women provided a MME or LARC 
method increased substantially between 2000-2017. MME provision increased less for 
women with SUD than women without SUD. However, a greater increase in LARC 
provision was observed for women with SUD. Compared to other substance-using 
women, women with OUD had the lowest increase in MME and LARC provision over 
the study period. The percentage of women provided a MME method increased more for 
women with SUD aged 15-20 compared to women without SUD of a similar age. In later 
study years, adolescent women with SUD had the highest absolute rates of contraceptive 
uptake across all age groups. Another important finding from this chapter includes that 
adolescent women with SUD aged 15-17 had the greatest increase in MME provision 
over the study period compared to other women of all age groups. Adolescent women 
aged 18-20 had the greatest increase in LARC provision over the study period.  
Patterns in postpartum contraceptive initiation 
Chapter 3 examined the postpartum contraceptive behaviors of women with OUD 
compared to women without OUD, including women with non-opoioid SUD and women 
without SUD. Associations between OUD and postpartum contraceptive initiation were 
examined at multiple time points, including within the immediate postpartum period and 
by 3, 6, and 12 months postpartum. Multiple regression and IPTW analyses were used to 
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obtain estimates, and predicted probabilities of MME initiation across time points were 
calculated from weighted regression models and graphed.  
Overall, findings indicated that women with OUD are less likely to initiate MME 
contraceptive methods in the extended postpartum period than women with non-opioid 
SUD and women without SUD. Multiple regression analysis showed that women with 
non-opioid SUD and women without SUD had significantly higher odds of initiating 
MME methods by 3 and 12 months postpartum than women with OUD. Women without 
SUD also had higher odds of postpartum contraceptive initiation by 6 months 
postpartum. Although the magnitude and direction of the estimates were similar in 
weighted regression models, only the associations for women without SUD reached 
statistical significance. Predicted probabilities were consistent with regression estimates 
and showed that women with OUD have a lower probability of initiating postpartum 
contraception by 3, 6, and 12 months postpartum in comparison to women without OUD. 
Results from multiple sensitivity analyses confirmed the main findings. 
Practices related to contraceptive counseling  
Chapter 4 investigated health care providers’ self-reported contraceptive 
counseling practices for their patients with SUD using a qualitative approach. Providers 
were queried about multiple aspects of their contraceptive counseling for patients with 
SUD, including the context in which counseling takes place, information shared at visits, 
and communication approaches. Data were analyzed using a thematic analysis approach, 
and five themes were constructed using inductive and deductive codes.   
Providers described several important considerations for providing contraceptive 
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care to patients with SUD, including, timing contraceptive discussions appropriately, 
tailoring pregnancy-related information, providing non judgmental, compassionate care, 
and respecting patients’ reproductive autonomy. Providers also shared how the medical, 
treatment, and psychosocial needs of their patients shape discussions around 
contraceptive methods. Because women with SUD have remarkably high rates of 
unintended pregnancy, innovative strategies to improve contraceptive outcomes among 
substance-using women are sorely needed. Appropriately timed, individualized 
contraceptive counseling may be one strategy to improve family planning service 
delivery and contraceptive outcomes for this population.  
Concluding remarks 
Dissertation strengths and limitations 
 This dissertation has several strengths and makes the following contributions to 
the literature. First, chapter 2 demonstrated the utility of adapting the NQF-endorsed 
CCM for use with subpopulations of women with SUD. This study also showed that the 
CCM could reliably be used to calculate MME and LARC provision trends over time 
with subpopulations. Second, no prior research has longitudinally examined 
contraceptive provision for women enrolled in the SC Medicaid program. With 18 years 
of administrative data, chapter 2 exhibited how trends in contraceptive provision among 
Medicaid beneficiaries coincided with the rise of the opioid epidemic and how 
contraceptive provision patterns changed over time according to participant 
characteristics. Third, chapters 2 and 3 were conducted with large sample sizes, which 
allowed for examination of the effect of SUD type on contraceptive provision and use 
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outcomes. Because of the large sample size, we were able to create multiple comparison 
groups for women with OUD in the chapter 3 study and to contribute an important 
finding that women with OUD may initiate postpartum contraception less frequently than 
women with other alcohol and drug disorders. Finally, chapter 4 included a diverse 
national sample of women’s health providers and increased our understanding of how 
contraceptive counseling is performed for women with SUD across the US. 
 This dissertation also has limitations. First, chapters 2 and 3 relied on 
administrative billing data for ascertainment of SUD, which would only appear in the 
data if the billed service was related to the SUD diagnosis. While it possible that we 
underestimated the percentage of women with SUD, administrative data provide a 
reasonable proxy for SUD identification and have been used extensively in substance 
abuse research. Second, while Medicaid claims data contain comprehensive medical 
information on beneficiaries, avoid biases inherent in self-report data, and are cost-
effective and convenient, they are collected for reimbursement and not research purposes 
and are therefore subject to missing data and coding errors. Third, Medicaid data contain 
limited information, so chapters 2 and 3 did not capture women who were using over-the-
counter contraceptives or account for important variables, such as pregnancy intent or 
quality of contraceptive counseling, that could influence contraceptive provision and use 
outcomes. Fourth, it is possible that the results observed in chapters 2 and 3 were 
attributable to misclassification of either the outcome or exposure variables, including 
users classified as non-users or vice versa. Fifth, findings from this dissertation may have 
limited generalizability. The quantitative study results may not be generalizable to 
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reproductive-age women outside of the SC Medicaid program, such as women in other 
states or women in SC who are uninsured or covered by private insurance, and findings 
from chapter 4 may not be generalizable to other health care providers. 
Implications and future research directions 
The findings presented here have important clinical implications for contraceptive 
care delivery for women with SUD. Providers should be aware that women with OUD 
may be less inclined to use contraception than women with other alcohol and drug 
disorders and should provide contraceptive counseling and education accordingly. Given 
data limitations and time constraints, this research could not elucidate why women with 
OUD may have differential contraceptive use behaviors than women with other types of 
SUD. Women with OUD experience unique barriers to contraceptive use and adherence, 
such as a perceived low risk of pregnancy due to irregular menses (1–5), which may be 
responsible for the observed study findings. Though understanding these barriers is 
beyond the scope of this dissertation, future efforts are needed to identify the particular 
barriers that may contribute to differential contraceptive use for women with OUD 
compared to women with other alcohol and drug disorders and to develop clinical and 
public health interventions to address these barriers. 
This dissertation found that provision of MME contraceptive methods among SC 
Medicaid beneficiaries has increased less over time for women with SUD than women 
without SUD. However, the opposite was true with regards to LARC. Consistent with 
other research (6,7), these results suggest that women with SUD in our sample had poorer 
uptake of and adherence to user-dependent forms of contraception. While the existing 
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literature states that SUD is associated with decreased contraceptive use prevalence of 
highly effective and effective methods (6,8), limited research to date has specifically 
examined contraceptive adherence among women with SUD. The only two studies to 
explore this topic have reported inconsistent findings (6,7). To develop and implement 
effective interventions to facilitate improved contraceptive compliance among women 
with SUD, it is important to assess patterns of adherence and discontinuation and factors 
related to correct and consistent contraceptive use in this population.  
Notably, our stratified analyses revealed that contraceptive provision was not 
lower among women with SUD than women without SUD in adolescent women aged 15-
20. Absolute rates of contraceptive provision for adolescent women with SUD were 
higher than for all other participants. This finding is inconsistent with national data 
showing that contraceptive use is higher among older than younger women (9) and 
suggests that younger women with SUD may not face the increased barriers to 
contraceptive access and continued use that are experienced by older substance-using 
women. Adolescent women with SUD may have increased family/social support and 
resources, such as transportation or increased financial resources, that facilitate family 
planning access and utilization. In addition, young people may have a regular pediatric or 
adult care provider, which would increase opportunities for accessing and using highly 
effective and effective contraceptive methods. Finding ways to keep women with SUD 
who are in their later reproductive years engaged with reproductive health services and 
the health care system in general is an important area of future research. SUD treatment 
locations may offer an opportunity to reach women throughout their childbearing years, 
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and co-location of family planning services into these settings has shown promise to 
remove barriers to contraceptive access (10,11).  
 Several potential areas for future research emerged from the health care provider 
interviews. Providers perceived that women with OUD taking daily buprenorphine may 
have better adherence to oral contraceptives than women not taking buprenorphine. 
Future research that examines the relationship between receipt of medication for OUD 
(MOUD), type of medication, and contraceptive adherence could help clinicians provide 
tailored contraceptive counseling for their patients with OUD. Studies examining the 
effect of MOUD initiation during pregnancy on postpartum contraceptive outcomes are 
also needed. Among providers that care for pregnant women, contraceptive counseling in 
the antepartum is standard practice, but there is wide variation in the initiation, frequency, 
and duration of prenatal contraceptive counseling. More research examining how these 
factors influence postpartum contraceptive use outcomes may inform guidelines for 
providing contraceptive counseling to pregnant women with SUD. A better 
understanding is also needed of women’s preferences for the frequency and timing of 
prenatal contraceptive discussions. 
  While the provider interviews revealed providers’ preferences related to 
communication approaches and information discussed during contraceptive counseling, 
additional studies are warranted to investigate patients’ preferences for patient-provider 
communication during counseling interactions. Such information would be useful to 
guide providers wishing to adopt a more patient-centered approach to contraceptive 
counseling. While women with SUD who desire contraceptives should have access to 
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them and many innovative strategies have been developed to increase that access, it is 
important that providers and family planning advocates strive for reproductive equity 
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Diagnosis and procedure codes used to identify alcohol and drug use disorders 
 
Diagnosis or 





















































































304.3x, 305.2x F12.1-F12.29   
Opioid use 
disorder 






























































































































































































































































ICD-9, International Classification of Disease, Ninth Revison; ICD-10, International 
Classification of Disease, Tenth Revision; HCPCS, Healthcare Common Procedure Coding 
System; NDC, National Drug Code 





Steps and codes for determining numerator and denominator for the clinical performance 
measures for contraceptive care 
 
 



























































































































































































































































































































































































































































































































































































































































































Discontinue   11976,  
 159 
implant 11982 
ICD-9, International Classification of Disease, Ninth Revison; ICD-10, International 
Classification of Disease, Tenth Revision; HCPCS, Healthcare Common Procedure Coding 
System; NDC, National Drug Code 
Notes: Codes listed above were used to calculate contraceptive care measures for years 2000-




Classification of rurality using United States Department of Agriculture 2003 and 2013 
Urban Influence Codes 
 
Metropolitan counties 
1 In large metro area of 1 million or more  residents 
2 In small metro area of less than 1 million residents 
Nonmetropolitan counties 
3 Micropolitan area adjacent to large metro area 
4 Noncore adjacent to large metro area 
5 Micropolitan area adjacent to small metro area 
6 
Noncore adjacent to small metro area and contains a town of at least 
2,500 residents 
7 
Noncore adjacent to small metro area and does not contain a town of 
at least 2,500 residents 
8 Micropolitan area not adjacent to a metro area 
9 
Noncore adjacent to micro area and contains a town of at least 2,500 
residents 
10 
Noncore adjacent to micro area and does not contain a town of at 
least 2,500 residents 
11 
Noncore not adjacent to metro or micro area and contains a town of at 
least 2,500 residents 
12 
Noncore not adjacent to metro or micro area and does not contain a 
town of at least 2,500 residents 
Notes: Metropolitan was classified as urban and non-metropolitan was classified as rural. 
 
 









Abbeville County 6 Rural 5 Rural 
Aiken County 2 Urban 2 Urban 
Allendale County 6 Rural 6 Rural 
Anderson County 2 Urban 2 Urban 
Bamberg County 9 Rural 9 Rural 
Barnwell County 6 Rural 6 Rural 
Beaufort County 8 Rural 2 Urban 
Berkeley County 2 Urban 2 Urban 
Calhoun County 2 Urban 2 Urban 
Charleston County 2 Urban 2 Urban 
Cherokee County 5 Rural 5 Rural 
Chester County 3 Rural 1 Urban 
Chesterfield County 4 Rural 4 Rural 
Clarendon County 6 Rural 6 Rural 
 161 
Colleton County 5 Rural 6 Rural 
Darlington County 2 Urban 2 Urban 
Dillon County 5 Rural 6 Rural 
Dorchester County 2 Urban 2 Urban 
Edgefield County 2 Urban 2 Urban 
Fairfield County 2 Urban 2 Urban 
Florence County 2 Urban 2 Urban 
Georgetown County 5 Rural 5 Rural 
Greenville County 2 Urban 2 Urban 
Greenwood County 5 Rural 5 Rural 
Hampton County 6 Rural 6 Rural 
Horry County 2 Urban 2 Urban 
Jasper County 5 Rural 2 Urban 
Kershaw County 2 Urban 2 Urban 
Lancaster County 3 Rural 1 Urban 
Laurens County 2 Urban 2 Urban 
Lee County 6 Rural 6 Rural 
Lexington County 2 Urban 2 Urban 
McCormick County 7 Rural 6 Rural 
Marion County 6 Rural 6 Rural 
Marlboro County 5 Rural 5 Rural 
Newberry County 5 Rural 5 Rural 
Oconee County 5 Rural 5 Rural 
Orangeburg County 5 Rural 5 Rural 
Pickens County 2 Urban 2 Urban 
Richland County 2 Urban 2 Urban 
Saluda County 2 Urban 2 Urban 
Spartanburg County 2 Urban 2 Urban 
Sumter County 2 Urban 2 Urban 
Union County 5 Rural 2 Urban 
Williamsburg County 6 Rural 6 Rural 
York County 1 Urban 1 Urban 
UIC, Urban Influence Code 
Notes: Classification of rurality for years 2000-2009 was based on 2003 Urban Influence Codes. 
















procedure DRG or MS-DRG ICD-9 ICD-10 
Delivery codes 370-375, 765-768, 
774-775 
  
V27.xx, 650,  
72.0-72.9, 73.22, 
73.59, 73.6, 74.0, 
74.1, 74.2, 74.4, 74.99 








or induced abortion 
(excluded) 
 630-637.92, 639.0-










Z37.7, Z38.3- Z38.8 
DRG, Diagnosis Related Group; MS-DRG, Medicare Severity-Diagnosis Related Group; ICD-9, 
International Classification of Disease, Ninth Revision; ICD-10, International Classification of 
Disease, Tenth Revision 






Diagnosis and procedure codes used to identify chronic conditions listed in the United 




procedure ICD-9 ICD-10 HCPCS 
Mental health 
diagnosis (excluding 






Breast cancer 174.x, 198.81, 
233.0 
D05, C50.0, C50.01x, C50.11x, 
C50.21x, C50.31x, C50.41x, 









Z68.41, Z68.42, Z68.43, Z68.44, 
Z68.45, 0DV64CZ, 0D164Z9, 
0D164ZA, 0D160ZA, 0D160ZB, 









I26, I80.1-I82  
Valvular heart disease 394.0-397.0, 
424.x, V43.3 
I05-I08, I34-I37, Z95.2, Z95.4  
Systematic lupus 
erythematosus 
710.0 M32.10, M32.9  
Liver cancer 155.x, 197.7, 
230.8, 235.3 
C22, D01.5, D37.6  






Chronic hypertension 362.11, 405.0x-
405.99 
H35.03x, I10-I15, I67.4, N26.2  
Stroke 430-438.9 I60-I69  
Migraine with aura 346.0x, 346.3x, 
346.5x, 346.6x,  
G43.10x, G423.11x, G43.40x, 
G43.41x, G43.50x, G43.51x, 
G43.60x, G43.61x 
 
Diabetes 250.0x-250.9x E10-E14  
Peripartum 
cardiomyopathy 
674.5x O90.3  
Malignant gestational 
trophoblastic disease 




Ovarian cancer 183.x, 198.6 C56, C57, C79.6x  
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Endometrial cancer 182.0, 182.1, 
182.8, 233.2 
C54, D07.0  
Thrombogenic 
mutations 
289.81 D68.5x  
Tuberculosis 010-018 A15-A19  
Sickle cell disease 282.6x D57.0x-D57.21x, D57.80-D57.81x  
Schistosomiasis with 
fibrosis of liver 















Z93.4, Z94.0, Z94.1, Z94.2, Z94.3, 
Z94.83, T86.1x-T86.4x, T86.81x, 
02YA0Z0, 02YA0Z1, 02YA0Z2, 
0FY00Z0, 0FY00Z1, 0FY00Z2, 
0FYG0Z0, 0FYG0Z1, 0FYG0Z2, 
0BYK0Z0, 0BYK0Z1, 0BYK0Z2, 
0BYL0Z0, 0BYL0Z1, 0BYL0Z2, 
0BYC0Z0, 0BYC0Z1, 0BYC0Z2, 
0BYD0Z0, 0BYD0Z1, 0BYD0Z2, 
0BYF0Z0, 0BYF0Z1, 0BYF0Z2, 
0BYG0Z0, 0BYG0Z1, 0BYG0Z2, 
0BYH0Z0, 0BYH0Z1, 0BYH0Z2, 
0BYJ0Z0, 0BYJ0Z1, 0BYJ0Z2, 
0BYK0Z0, 0BYK0Z1, 0BYK0Z2, 
0BYL0Z0, 0BYL0Z1, 0BYL0Z2, 
0BYM0Z0, 0BYM0Z1, 0BYM0Z2, 
0TS00ZZ, 0TS10ZZ, 0TY00Z0, 





















ICD-9, International Classification of Disease, Ninth Revision; ICD-10, International 





Moderator guide used for the interviews 
 
 
Hello, thank you for joining me today. My name is Betsy, and I am a research assistant at 
Clemson University. How are you today? 
 
Thank you for your time and your interest in this study. Before we begin, I would like to 
make sure that you qualify for the study.  
 
Are you in a role where you provide contraceptive counseling to women with substance 
use disorder (SUDs)?  
 
Exclusion criteria: 
¾ Does not provide contraceptive counseling to women with SUDs as part of his/her 
duties 
¾ Non-provider staff (i.e. other non-provider staff in the office setting, such as 
administrative staff) 
¾ Non-English speaking providers 
 
AFTER PROVIDER ANSWERS: Great, then before we start, I wanted to tell you a little 
bit about the study. I am a PhD student at Clemson University. For my dissertation 
project, I am trying to learn about how healthcare practioners with prescriptive authority 
are providing contraceptive counseling to women with substance use disorders (SUD). 
Today, I am specifically interested in how you provide counseling to women with drug 
and alcohol use disorders, not tobacco use disorders.  
 
Our discussion will last no more than 30 minutes, to be respectful of your time, but there 
is no time limit. There are no right or wrong answers in this discussion, so please feel 
free to share your practices. We will not retain any personal identifying information for 
this study. Do you have any questions for me? 
 
Please feel free to stop me and ask questions at any time during our discussion. Also, 
since we will be speaking for a while today, and it’s hard for me to remember 
everything, would it be okay if I recorded our conversation?  
 
Thank you! We will transcribe your responses, ensuring confidentiality, and digital 






Question 1: How long have you been providing contraceptive counseling to women with 
SUDs? 
 
Question 2: How do you define contraceptive counseling at your practice? 
 
LEAD IN: Great, the remainder of my questions today will be about your experience 




1) Tell me about your contraceptive counseling discussions with your patients who have 
SUDs. 
 
Probes: ideal time period, particular trimester or visit, how often, who participates 
 
 
2) Tell me about contraception information that you share with patients who have SUDs. 
 
Probes: safety, efficacy, side effects, correct use, address concerns, correct 
misconceptions, dual STI counseling, format 
 
 
3) Help me understand what contraceptive counseling approaches you have found most 
effective for women with SUDs.  
 
Probes: dialoguing, decision-making, relationship, partners, follow-up 
 
 
4) As I'm listening to you, I am wondering if you can help me understand how 
counseling may differ for someone with an active SUD as compared to someone in 
recovery. 
 
Probes: substance of choice. information, approaches, time period of counseling 
 
 
5) I’m also wondering, since I'm not a clinician like you, if you can help me understand 
how counseling someone without a SUD might compare to counseling someone with 
one. 
 
Probes: information, approaches, time period of counseling 
 
 
6) As a provider, help me understand what contraceptive counseling resources you 
would like in order to support your efforts serving women with SUDs. 
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Probes: More CEU opportunities, more time, more mid-level staff to help with education, 




Before we end, would you mind providing some quick demographic information. I am 
asking these questions of everyone that I interview. Please feel free to decline to answer 
any of these questions. 
 
What is your gender:  
x Male or Female 
What is your race/ethnicity:  
x non-Hispanic white; non-Hispanic black; Hispanic or Latino; Asian; American 
Indian; Other 
What is your age group: 
x Between 25-34; 35-44; 45-54; 55-64 
What is your specialty? 
x Open ended 
What population do you serve? 
x Open ended 
About how many patients do you see in your practice? 
x Open-ended 






Do you have anything else you would like to add? Do you have any questions for me? 
Thank you very much for your time today.  
 
  
 
 
 
 
 
 
 
